BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harris CC. Structure and Function of the p53 Tumor Suppressor Gene: Clues for Rational Cancer Therapeutic Strategies. JNCI Journal of the National Cancer Institute 1996;88:1442-55. [DOI: 10.1093/jnci/88.20.1442] [Cited by in Crossref: 404] [Cited by in F6Publishing: 367] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MDC, Vilana R, Rodés J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution: Transarterial Embolization Versus Symptomatic Treatment in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized, Controlled Trial. Hepatology 1998;27:1578-83. [DOI: 10.1002/hep.510270617] [Cited by in Crossref: 376] [Cited by in F6Publishing: 358] [Article Influence: 19.8] [Reference Citation Analysis]
2 O'donnell RT, Denardo SJ, Miers LA, Kukis DL, Mirick GR, Kroger LA, Denardo GL. Combined Modality Radioimmunotherapy with Taxol and 90 Y-LYM-1 for Raji Lymphoma Xenografts. Cancer Biotherapy and Radiopharmaceuticals 1998;13:351-61. [DOI: 10.1089/cbr.1998.13.351] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
3 Casson AG, Schrump DS. BIOLOGY AND EPIDEMIOLOGY OF MALIGNANT ESOPHAGEAL CARCINOMA. Pearson's Thoracic and Esophageal Surgery. Elsevier; 2008. pp. 439-53. [DOI: 10.1016/b978-0-443-06861-4.50191-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Kim R, Tanabe K, Emi M, Uchida Y, Inoue H, Toge T. Inducing cancer cell death by targeting transcription factors: . Anti-Cancer Drugs 2003;14:3-11. [DOI: 10.1097/00001813-200301000-00002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
5 Nagaraj S, Pisarev V, Kinarsky L, Sherman S, Muro-Cacho C, Altieri DC, Gabrilovich DI. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother 2007;30:169-79. [PMID: 17471164 DOI: 10.1097/01.cji.0000211329.83890.ba] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
6 Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, Geller DA, Will H, Harris CC. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA. 1997;94:14707-14712. [PMID: 9405677 DOI: 10.1073/pnas.94.26.14707] [Cited by in Crossref: 219] [Cited by in F6Publishing: 231] [Article Influence: 9.1] [Reference Citation Analysis]
7 Hill KA, Sommer SS. p53 As a mutagen test in breast cancer. Environ Mol Mutagen 2002;39:216-27. [DOI: 10.1002/em.10065] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
8 Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Br J Cancer 1998;77:1562-7. [PMID: 9635829 DOI: 10.1038/bjc.1998.257] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 2.6] [Reference Citation Analysis]
9 Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 2003;21:277-84. [PMID: 12619113 DOI: 10.1002/humu.10190] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 4.6] [Reference Citation Analysis]
10 Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat. 2004;11:383-393. [PMID: 15357643 DOI: 10.1111/j.1365-2893.2004.00521.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 122] [Article Influence: 7.2] [Reference Citation Analysis]
11 Ghosh R, Bhowmik S, Guha D. 9-Phenyl acridine exhibits antitumour activity by inducing apoptosis in A375 cells. Mol Cell Biochem 2012;361:55-66. [DOI: 10.1007/s11010-011-1088-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
12 Seemayer CA, Seemayer NH, Dürmüller U, Gudat F, Schaub S, Hirsch HH, Mihatsch MJ. BK virus large T and VP-1 expression in infected human renal allografts. Nephrol Dial Transplant 2008;23:3752-61. [PMID: 18784088 DOI: 10.1093/ndt/gfn470] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
13 Tomasini R, Samir AA, Pebusque MJ, Calvo EL, Totaro S, Dagorn JC, Dusetti NJ, Iovanna JL. P53-dependent expression of the stress-induced protein (SIP). Eur J Cell Biol. 2002;81:294-301. [PMID: 12067065 DOI: 10.1078/0171-9335-00248] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 3.2] [Reference Citation Analysis]
14 He F, Xia Y, Liu H, Li J, Wang C. P53 codon 72 Arg/Pro polymorphism and glioma risk: an updated meta-analysis. Tumor Biol 2013;34:3121-30. [DOI: 10.1007/s13277-013-0880-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
15 Cicinnati VR, Dworacki G, Albers A, Beckebaum S, Tüting T, Kaczmarek E, Deleo AB. Impact of p53-based immunization on primary chemically-induced tumors: p53 Immunotherapy of MCA-Treated Mice. Int J Cancer 2005;113:961-70. [DOI: 10.1002/ijc.20686] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
16 Matsuda K, Miyoshi H, Hiraoka K, Yokoyama S, Haraguchi T, Hashiguchi T, Hamada T, Shiba N, Ohshima K. Clinicopathological and prognostic value of transforming acidic coiled-coil-containing protein 3 (TACC3) expression in soft tissue sarcomas. PLoS One 2017;12:e0188096. [PMID: 29135996 DOI: 10.1371/journal.pone.0188096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Hershey AE, Dubielzig RR, Padilla ML, Helfand SC. Aberrant p53 expression in feline vaccine-associated sarcomas and correlation with prognosis. Vet Pathol 2005;42:805-11. [PMID: 16301577 DOI: 10.1354/vp.42-6-805] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
18 Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cantù G, Pierotti MA, Pilotti S. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol 2004;22:4901-6. [PMID: 15611505 DOI: 10.1200/JCO.2004.05.071] [Cited by in Crossref: 69] [Cited by in F6Publishing: 19] [Article Influence: 4.1] [Reference Citation Analysis]
19 Blaszyk H, Hartmann A, Cunningham JM, Schaid D, Wold LE, Kovach JS, Sommer SS. A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int J Cancer 2000;89:32-8. [PMID: 10719728 DOI: 10.1002/(sici)1097-0215(20000120)89:1<32::aid-ijc6>3.0.co;2-g] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
20 Kanzler S, Galle PR. Apoptosis and the liver. Semin Cancer Biol. 2000;10:173-184. [PMID: 10936067 DOI: 10.1006/scbi.2000.0318] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 5.1] [Reference Citation Analysis]
21 Pruschy M, Resch H, Shi YQ, Aalame N, Glanzmann C, Bodis S. Ceramide triggers p53-dependent apoptosis in genetically defined fibrosarcoma tumour cells. Br J Cancer 1999;80:693-8. [PMID: 10360645 DOI: 10.1038/sj.bjc.6690411] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
22 Park EK, Lee JC, Park JW, Bang SY, Yi SA, Kim BK, Park JH, Kwon SH, You JS, Nam SW. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis. 2015;6:e1964. [PMID: 26539911 DOI: 10.1038/cddis.2015.313] [Cited by in Crossref: 45] [Cited by in F6Publishing: 52] [Article Influence: 6.4] [Reference Citation Analysis]
23 Feinmesser M, Halpern M, Fenig E, Tsabari C, Hodak E, Sulkes J, Brenner B, Okon E. Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome? Hum Pathol 1999;30:1367-72. [PMID: 10571519 DOI: 10.1016/s0046-8177(99)90070-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
24 Patel S, Player MR. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Investig Drugs. 2008;17:1865-1882. [PMID: 19012502 DOI: 10.1517/13543780802493366] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 5.5] [Reference Citation Analysis]
25 Banerjee R, Basu G, Roy S, Chène P. Aib-based peptide backbone as scaffolds for helical peptide mimics: Aib-based backbone as scaffolds for helical peptide mimics. The Journal of Peptide Research 2002;60:88-94. [DOI: 10.1034/j.1399-3011.2002.201005.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
26 Hoofnagle JH. Hepatocellular carcinoma: summary and recommendations. Gastroenterology 2004;127:S319-23. [PMID: 15508100 DOI: 10.1053/j.gastro.2004.09.047] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
27 Piplani H, Vaish V, Rana C, Sanyal SN. Up-regulation of p53 and mitochondrial signaling pathway in apoptosis by a combination of COX-2 inhibitor, Celecoxib and Dolastatin 15, a marine mollusk linear peptide in experimental colon carcinogenesis. Mol Carcinog 2013;52:845-58. [PMID: 22623379 DOI: 10.1002/mc.21925] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
28 Gelfi C, Viganó A, Curcio M, Righetti PG, Righetti SC, Corna E, Zunino F. Single-strand conformation polymorphism analysis by capillary zone electrophoresis in neutral pH buffer. Electrophoresis 2000;21:785-91. [PMID: 10733223 DOI: 10.1002/(SICI)1522-2683(20000301)21:4<785::AID-ELPS785>3.0.CO;2-E] [Cited by in Crossref: 13] [Article Influence: 0.6] [Reference Citation Analysis]
29 Shinoura N, Sakurai S, Shibasaki F, Asai A, Kirino T, Hamada H. Co-transduction of Apaf-1 and caspase-9 highly enhances p53-mediated apoptosis in gliomas. Br J Cancer. 2002;86:587-595. [PMID: 11870542 DOI: 10.1038/sj.bjc.6600061] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
30 Du J, Xu R. RORα, a potential tumor suppressor and therapeutic target of breast cancer. Int J Mol Sci 2012;13:15755-66. [PMID: 23443091 DOI: 10.3390/ijms131215755] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
31 Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F. p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma. JCO 2000;18:3936-45. [DOI: 10.1200/jco.2000.18.23.3936] [Cited by in Crossref: 102] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
32 Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR, Mitsui Y, Kaul SC. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem 1998;273:29586-91. [PMID: 9792667 DOI: 10.1074/jbc.273.45.29586] [Cited by in Crossref: 164] [Cited by in F6Publishing: 148] [Article Influence: 6.8] [Reference Citation Analysis]
33 Dubey AR, Jagtap YA, Kumar P, Patwa SM, Kinger S, Kumar A, Singh S, Prasad A, Jana NR, Mishra A. Biochemical strategies of E3 ubiquitin ligases target viruses in critical diseases. J Cell Biochem 2021. [PMID: 34520596 DOI: 10.1002/jcb.30143] [Reference Citation Analysis]
34 Kim SS, Rait A, Rubab F, Rao AK, Kiritsy MC, Pirollo KF, Wang S, Weiner LM, Chang EH. The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. Mol Ther. 2014;22:278-291. [PMID: 24113515 DOI: 10.1038/mt.2013.231] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
35 Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 2004;63:651-5. [PMID: 15072872 DOI: 10.1016/j.urology.2003.11.011] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 3.7] [Reference Citation Analysis]
36 Chen H, Wang LD, Guo M, Gao SG, Guo HQ, Fan ZM, Li JL. Alterations of p53 and PCNA in cancer and adjacent tissues from concurrent carcinomas of the esophagus and gastric cardia in the same patient in Linzhou, a high incidence area for esophageal cancer in northern China. World J Gastroenterol 2003; 9(1): 16-21 [PMID: 12508343 DOI: 10.3748/wjg.v9.i1.16] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
37 Mitsudomi T, Hatooka S, Shinoda M, Suyama M, Yatabe Y, Kuwabara M, Nishio M, Gotoh K, Ogawa M, Takahashi T, Takahashi T, Suzuki S, Ariyoshi Y. Clinical Implications of p53 Autoantibodies in the Sera of Patients With Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute 1998;90:1563-8. [DOI: 10.1093/jnci/90.20.1563] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.4] [Reference Citation Analysis]
38 Lam SK, Ng TB. Apoptosis of human breast cancer cells induced by hemagglutinin from Phaseolus vulgaris cv. Legumi secchi. Food Chemistry 2011;126:595-602. [DOI: 10.1016/j.foodchem.2010.11.049] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
39 Mitsudomi T, Yatabe Y, Koshikawa T, Hatooka S, Shinoda M, Suyama M, Sugiura T, Ogawa M, Takahashi T. Mutations of the p53 tumor suppressor gene as clonal marker for multiple primary lung cancers. The Journal of Thoracic and Cardiovascular Surgery 1997;114:354-60. [DOI: 10.1016/s0022-5223(97)70180-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
40 Beerheide W, Tan YJ, Teng E, Ting AE, Jedpiyawongse A, Srivatanakul P. Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas. Biochem Biophys Res Commun. 2000;273:54-61. [PMID: 10873563 DOI: 10.1006/bbrc.2000.2891] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 1.8] [Reference Citation Analysis]
41 Phillips H. The Role of the p53 Tumour Suppressor Gene in Human Breast Cancer. Clinical Oncology 1999;11:148-55. [DOI: 10.1053/clon.1999.9032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
42 Russo IH, Russo J. Primary prevention of breast cancer by hormone-induced differentiation. Recent Results Cancer Res 2007;174:111-30. [PMID: 17302191 DOI: 10.1007/978-3-540-37696-5_11] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
43 Pinedo HM, Giaccone G. Chemotherapy. The Lancet 1997;349:S7-9. [DOI: 10.1016/s0140-6736(97)90012-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Niklinska W, Burzykowski T, Chyczewski L, Rusin MR, Furman M, Laudanski J, Chyczewska E, Sulik M, Niklinski J. p53 gene mutation and protein expression in operable non-small cell lung cancer in Poland: . European Journal of Cancer Prevention 2000;9:81-8. [DOI: 10.1097/00008469-200004000-00003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
45 Schroeder M, Mass MJ. CpG Methylation Inactivates the Transcriptional Activity of the Promoter of the Humanp53Tumor Suppressor Gene. Biochemical and Biophysical Research Communications 1997;235:403-6. [DOI: 10.1006/bbrc.1997.6796] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 2.2] [Reference Citation Analysis]
46 Ho WL, Chang JW, Tseng RC, Chen JT, Chen CY, Jou YS, Wang YC. Loss of heterozygosity at loci of candidate tumor suppressor genes in microdissected primary non-small cell lung cancer. Cancer Detect Prev 2002;26:343-9. [PMID: 12518864 DOI: 10.1016/s0361-090x(02)00088-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
47 Hellborg F, Qian W, Mendez-vidal C, Asker C, Kost-alimova M, Wilhelm M, Imreh S, Wiman KG. Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein. Oncogene 2001;20:5466-74. [DOI: 10.1038/sj.onc.1204722] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
48 Benjamin CL, Melnikova VO, Ananthaswamy HN. p53 Protein and Pathogenesis of Melanoma and Nonmelanoma Skin Cancer. In: Reichrath J, editor. Sunlight, Vitamin D and Skin Cancer. New York: Springer; 2008. pp. 265-82. [DOI: 10.1007/978-0-387-77574-6_21] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Reference Citation Analysis]
49 Kim JH, Jung JH, Lee HJ, Sim DY, Im E, Park J, Park WY, Ahn CH, Shim BS, Kim B, Kim SH. UBE2M Drives Hepatocellular Cancer Progression as a p53 Negative Regulator by Binding to MDM2 and Ribosomal Protein L11. Cancers (Basel) 2021;13:4901. [PMID: 34638383 DOI: 10.3390/cancers13194901] [Reference Citation Analysis]
50 Lu Q, Tan YH, Luo R. Molecular dynamics simulations of p53 DNA-binding domain. J Phys Chem B 2007;111:11538-45. [PMID: 17824689 DOI: 10.1021/jp0742261] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
51 Lou F, Zhang Y, Song N, Ji D, Gao T. Comprehensive Transcriptome Analysis Reveals Insights into Phylogeny and Positively Selected Genes of Sillago Species. Animals (Basel) 2020;10:E633. [PMID: 32272562 DOI: 10.3390/ani10040633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
52 Srikantan V, Srivastava S. Molecular Dissection of the Prostate Cancer Genome. In: Hofmann R, Heidenreich A, Moul JW, editors. Prostate Cancer. Berlin: Springer Berlin Heidelberg; 2003. pp. 25-40. [DOI: 10.1007/978-3-642-56321-8_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Kuchur OA, Kuzmina DO, Dukhinova MS, Shtil AA. The p53 Protein Family in the Response of Tumor Cells to Ionizing Radiation: Problem Development. Acta Naturae 2021;13:65-76. [PMID: 34707898 DOI: 10.32607/actanaturae.11247] [Reference Citation Analysis]
54 Luu TH, Bard JM, Carbonnelle D, Chaillou C, Huvelin JM, Bobin-Dubigeon C, Nazih H. Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells. Cell Oncol (Dordr) 2018;41:13-24. [PMID: 28993998 DOI: 10.1007/s13402-017-0353-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
55 Fathima Hurmath K, Ramaswamy P, Nandakumar DN. IL-1β microenvironment promotes proliferation, migration, and invasion of human glioma cells: Proliferation, migration, invasion by IL-1β. Cell Biol Int 2014;38:1415-22. [DOI: 10.1002/cbin.10353] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
56 He XT, Fan XM, Zha XL. Ghrelin inhibits 5-fluorouracil-induced apoptosis in colonic cancer cells. J Gastroenterol Hepatol. 2011;26:1169-1173. [PMID: 21375586 DOI: 10.1111/j.1440-1746.2011.06715.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
57 Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998;188:2033-2045. [PMID: 9841917 DOI: 10.1084/jem.188.11.2033] [Cited by in Crossref: 537] [Cited by in F6Publishing: 506] [Article Influence: 23.3] [Reference Citation Analysis]
58 Das A, Tan WL, Smith DR. p53 point mutation is rare in meningiomas from Singaporean patients. Asian J Surg 2005;28:7-10. [PMID: 15691789 DOI: 10.1016/S1015-9584(09)60249-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
59 Xirodimas DP, Lane DP. Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling. J Biol Chem 1999;274:28042-9. [PMID: 10488156 DOI: 10.1074/jbc.274.39.28042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
60 Aoki S, Higuchi K, Isozumi N, Matsui K, Miyamoto Y, Itoh N, Tanaka K, Kobayashi M. Differentiation in Chronic Myelogenous Leukemia Cell K562 by Spongean Sesterterpene. Biochemical and Biophysical Research Communications 2001;282:426-31. [DOI: 10.1006/bbrc.2001.4588] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
61 Fukami T, Nakasu S, Baba K, Nakajima M, Matsuda M. Hyperthermia induces translocation of apoptosis-inducing factor (AIF) and apoptosis in human glioma cell lines. J Neurooncol. 2004;70:319-331. [PMID: 15662973 DOI: 10.1007/s11060-004-9168-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
62 Byun DS, Chae KS, Ryu BK, Lee MG, Chi SG. Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma. Int J Cancer. 2002;98:718-723. [PMID: 11920641 DOI: 10.1002/ijc.10253] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
63 Goldman R, Shields PG. Food Mutagens. The Journal of Nutrition 2003;133:965S-73S. [DOI: 10.1093/jn/133.3.965s] [Cited by in Crossref: 99] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
64 Sionov RV, Haupt Y. Apoptosis by p53: mechanisms, regulation, and clinical implications. Springer Semin Immunopathol 1998;19:345-62. [PMID: 9540161 DOI: 10.1007/BF00787230] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
65 Schnitt SJ. Traditional and newer pathologic factors. J Natl Cancer Inst Monogr 2001;:22-6. [PMID: 11773288 DOI: 10.1093/oxfordjournals.jncimonographs.a003456] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
66 Yu F, Zheng W, Wang M, Bender W, Cheerva A, Miller J. The effect of 17β-estradiol-DNA adducts on the replication of exon # 5 of the human suppressor gene p53. FEBS Letters 1999;454:7-10. [DOI: 10.1016/s0014-5793(99)00769-3] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
67 Tudzarova-Trajkovska S, Wesierska-Gadek J. Strong induction of p73 protein in vivo coincides with the onset of apoptosis in rat liver after treatment with the hepatocarcinogen N-nitrosomorpholine (NNM). J Cell Biochem. 2003;90:837-855. [PMID: 14587038 DOI: 10.1002/jcb.10678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
68 Chiarugi V, Magnelli L, Cinelli M. Role of P53 Mutations in the Radiosensitivity Status of Tumor Cells. Tumori 1998;84:517-20. [DOI: 10.1177/030089169808400501] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
69 Trukhanova LS, Hong HL, Sills RC, Bowser AD, Gaul B, Boorman GA, Turusov VS, Devereux TR, Dixon D. Predominant p53 G→A Transition Mutation and Enhanced Cell Proliferation in Uterine Sarcomas of CBA Mice Treated with 1,2-Dimethylhydrazine. Toxicol Pathol 1998;26:367-74. [DOI: 10.1177/019262339802600310] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
70 Benjamin CL, Ananthaswamy HN. p53 and the pathogenesis of skin cancer. Toxicol Appl Pharmacol 2007;224:241-8. [PMID: 17270229 DOI: 10.1016/j.taap.2006.12.006] [Cited by in Crossref: 109] [Cited by in F6Publishing: 83] [Article Influence: 6.8] [Reference Citation Analysis]
71 Al-Kashwan TA, Houshmand M, Al-Janabi A, Melconian AK, Al-Abbasi D, Al-Musawi MN, Rostami M, Yasseen AA. Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards. BMC Res Notes. 2012;5:466. [PMID: 22929185 DOI: 10.1186/1756-0500-5-466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Musumarra G, Trovato-salinaro A, Scirè S, Foti A, Barresi V, Fortuna CG, Strazzulla G, Condorelli DF. Identification of genes involved in radiation-induced G1 arrest. J Chemometrics 2007;21:398-405. [DOI: 10.1002/cem.1080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
73 Miettinen HE, Järvinen TAH, Kellner U, Kauraniemi P, Parwaresch R, Rantala I, Kalimo H, Paljärvi L, Isola J, Haapasalo H. High topoisomerase IIα expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas: Topoisomerase IIα expression in oligodendrogliomas. Neuropathology and Applied Neurobiology 2000;26:504-12. [DOI: 10.1046/j.1365-2990.2000.00282.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
74 Trevisani F, De Notariis S, Rossi C, Bernardi M. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol. 2001;32:383-389. [PMID: 11319307 DOI: 10.1097/00004836-200105000-00005] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 3.9] [Reference Citation Analysis]
75 Newton HB. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors Part 4: p53 signaling pathway. Expert Review of Anticancer Therapy 2014;5:177-91. [DOI: 10.1586/14737140.5.1.177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
76 Gupta P, Venugopal SK. Augmenter of liver regeneration: A key protein in liver regeneration and pathophysiology. Hepatol Res. 2018;48:587-596. [PMID: 29633440 DOI: 10.1111/hepr.13077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
77 Shen L, Zhang S, Wang K, Wang X. Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population. Front Oncol 2021;11:740227. [PMID: 34926254 DOI: 10.3389/fonc.2021.740227] [Reference Citation Analysis]
78 Qin C, Nguyen T, Stewart J, Samudio I, Burghardt R, Safe S. Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor kappaB/CCAAT-binding transcription factor-1 complex. Mol Endocrinol 2002;16:1793-809. [PMID: 12145335 DOI: 10.1210/me.2002-0006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
79 Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S, Fu CG, Takenoue T, Tsuruo T, Muto T. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer. 1998;78:986-992. [PMID: 9792140 DOI: 10.1038/bjc.1998.617] [Cited by in Crossref: 103] [Cited by in F6Publishing: 105] [Article Influence: 4.3] [Reference Citation Analysis]
80 Laytragoon-Lewin N, Rossmann ED, Castro J, Mellstedt H. Significance of phosphotyrosine proteins, Bcl-2 and p53 for apoptosis in resting B-chronic lymphocytic leukemia (CLL) cells. Int J Cancer 2002;97:344-8. [PMID: 11774286 DOI: 10.1002/ijc.1616] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
81 Apiyo D, Wittung-Stafshede P. Unique complex between bacterial azurin and tumor-suppressor protein p53. Biochem Biophys Res Commun 2005;332:965-8. [PMID: 15913547 DOI: 10.1016/j.bbrc.2005.05.038] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
82 Li C, Shridhar K, Liu J. Molecular Characterization of Oncostatin M-induced Growth Arrest of MCF-7 Cells Expressing a Temperature-Sensitive Mutant of p53. Breast Cancer Res Treat 2003;80:23-37. [DOI: 10.1023/a:1024483017549] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
83 Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562-9. [PMID: 11896105 DOI: 10.1200/JCO.2002.20.6.1562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 60] [Article Influence: 0.4] [Reference Citation Analysis]
84 Saini KS, Hamidullah, Ashraf R, Mandalapu D, Das S, Siddiqui MQ, Dwivedi S, Sarkar J, Sharma VL, Konwar R. New orally active DNA minor groove binding small molecule CT-1 acts against breast cancer by targeting tumor DNA damage leading to p53-dependent apoptosis: CT-1 INDUCES DNA DAMAGE AND p53 DEPENDENT CELL DEATH. Mol Carcinog 2017;56:1266-80. [DOI: 10.1002/mc.22588] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
85 Lang FF, yung WA, Sawaya R, Tofilon PJ. Adenovirus-mediated p53 Gene Therapy for Human Gliomas. Neurosurgery 1999;45:1093-104. [DOI: 10.1097/00006123-199911000-00016] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 2.7] [Reference Citation Analysis]
86 Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007;98:1803-1808. [PMID: 17784873 DOI: 10.1111/j.1349-7006.2007.00603.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 73] [Article Influence: 11.0] [Reference Citation Analysis]
87 Kook SH, Son YO, Chung SW, Lee SA, Kim JG, Jeon YM, Lee JC. Caspase-independent death of human osteosarcoma cells by flavonoids is driven by p53-mediated mitochondrial stress and nuclear translocation of AIF and endonuclease G. Apoptosis. 2007;12:1289-1298. [PMID: 17356895 DOI: 10.1007/s10495-007-0056-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
88 Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N, Viano I, Colangelo D, Leone R, Apostoli P. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochem Pharmacol. 1998;55:1247-1254. [PMID: 9719480 DOI: 10.1016/s0006-2952(97)00599-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
89 Agra RM, Teijeira-fernández E, Pascual-figal D, Sánchez-más J, Fernández-trasancos Á, González-juanatey JR, Eiras S. Adiponectin and p53 mRNA in epicardial and subcutaneous fat from heart failure patients. Eur J Clin Invest 2014;44:29-37. [DOI: 10.1111/eci.12186] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
90 Nogueira M, Kim HL. Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol 2008;26:113-24. [PMID: 18312928 DOI: 10.1016/j.urolonc.2007.03.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
91 Okamoto K, Shinoura N, Egawa N, Asai A, Kirino T, Shibasaki F, Shitara N. Adenovirus-mediated transfer of p53 augments hyperthermia-induced apoptosis in U251 glioma cells. Int J Radiat Oncol Biol Phys. 2001;50:525-531. [PMID: 11380242 DOI: 10.1016/S0360-3016(01)01474-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
92 Nawa A, Obata N, Kikkawa F, Kawai M, Nagasaka T, Goto S, Nishimori K, Nakashima N. Prognostic factors of patients with yolk sac tumors of the ovary. American Journal of Obstetrics and Gynecology 2001;184:1182-8. [DOI: 10.1067/mob.2001.113323] [Cited by in Crossref: 82] [Cited by in F6Publishing: 67] [Article Influence: 3.9] [Reference Citation Analysis]
93 Winiecka-Klimek M, Szybka M, Rieske P, Piaskowski S, Bienkowski M, Walczak M, Pacholczyk M, Rostkowski M, Zieba J, Banaszczyk M, Hulas-Bigoszewska K, Peciak J, Pawliczak R, Stoczynska-Fidelus E. PIN3 duplication may be partially responsible for TP53 haploinsufficiency. BMC Cancer 2014;14:669. [PMID: 25223755 DOI: 10.1186/1471-2407-14-669] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
94 Kandioler-eckersberger D, Kappel S, Mittlböck M, Dekan G, Ludwig C, Janschek E, Pirker R, Wolner E, Eckersberger F. The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery 1999;117:744-50. [DOI: 10.1016/s0022-5223(99)70295-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
95 O'donnell RT, Denardo SJ, Miers LA, Lamborn KR, Kukis DL, Denardo GL, Meyers FJ. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and90yttrium-DOTA-peptide-ChL6. Prostate 2002;50:27-37. [DOI: 10.1002/pros.10029] [Cited by in Crossref: 55] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
96 Ahmad N, Feyes DK, Agarwal R, Mukhtar H. Photodynamic therapy results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and apoptosis. Proc Natl Acad Sci U S A 1998;95:6977-82. [PMID: 9618524 DOI: 10.1073/pnas.95.12.6977] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 2.9] [Reference Citation Analysis]
97 Shao J, Fujiwara T, Kadowaki Y, Fukazawa T, Waku T, Itoshima T, Yamatsuji T, Nishizaki M, Roth JA, Tanaka N. Overexpression of the Wild-type P53 Gene Inhibits NF-κB Activity and Synergizes with Aspirin to Induce Apoptosis in Human Colon Cancer Cells. Oncogene. 2000;19:726-736. [PMID: 10698490 DOI: 10.1038/sj.onc.1203383] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 4.4] [Reference Citation Analysis]
98 Jan YY, Yeh TS, Yeh JN, Yang HR, Chen MF. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. Ann Surg 2004;240:89-94. [PMID: 15213623 DOI: 10.1097/01.sla.0000129492.95311.f2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
99 Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T, Minei S, Shimura S, Irie A, Kameya T, Baba S. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002;59:615-20. [PMID: 11927338 DOI: 10.1016/s0090-4295(01)01601-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
100 Morshaeuser L, May M, Burger M, Otto W, Hutterer GC, Pichler M, Klatte T, Wild P, Buser L, Brookman-May S. p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models. Urol Oncol 2018;36:94.e15-21. [PMID: 29221641 DOI: 10.1016/j.urolonc.2017.11.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
101 Norberg T, Lennerstrand J, Inganäs M, Bergh J. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection ofp53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 1998;79:376-83. [DOI: 10.1002/(sici)1097-0215(19980821)79:4<376::aid-ijc12>3.0.co;2-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
102 Otero-garcia JE, Youssef E, Enamorado II, Du W, Yoo GH, Merati K, Kewson D, Lonardo F, Jacobs JR, Kim H. Prognostic significance of p53 and FHIT in advanced oropharyngeal carcinoma. American Journal of Otolaryngology 2004;25:231-9. [DOI: 10.1016/j.amjoto.2004.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
103 Lane D. The promise of molecular oncology. Lancet 1998;351 Suppl 2:SII17-20. [PMID: 9606362 DOI: 10.1016/s0140-6736(98)90328-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
104 Li X, Xing D, Wang J, Zhu DB, Zhang L, Chen XJ, Sun FY, Hong A. Effects of IκBα and its mutants on NF-κB and p53 signaling pathways. World J Gastroenterol 2006; 12(41): 6658-6664 [PMID: 17075980 DOI: 10.3748/wjg.v12.i41.6658] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
105 Leonard K, Marugan JJ, Raboisson P, Calvo R, Gushue JM, Koblish HK, Lattanze J, Zhao S, Cummings MD, Player MR, Maroney AC, Lu T. Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity. Bioorganic & Medicinal Chemistry Letters 2006;16:3463-8. [DOI: 10.1016/j.bmcl.2006.04.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
106 Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, Schwartz AG, Vahakangas KH, Samet JM. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2009;15:5646-61. [PMID: 19755392 DOI: 10.1158/1078-0432.CCR-09-0377] [Cited by in Crossref: 103] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
107 Le QU, Lay HL, Wu MC. The isolation, structural characterization, and anticancer activity from the aerial parts of Cymbopogon flexuosus. J Food Biochem 2019;43:e12718. [PMID: 31353668 DOI: 10.1111/jfbc.12718] [Reference Citation Analysis]
108 Offner S, Schmaus W, Witter K, Baretton GB, Schlimok G, Passlick B, Riethmüller G, Pantel K. p53 gene mutations are not required for early dissemination of cancer cells. Proc Natl Acad Sci U S A 1999;96:6942-6. [PMID: 10359818 DOI: 10.1073/pnas.96.12.6942] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
109 Albers AE, Ferris RL, Kim GG, Chikamatsu K, Deleo AB, Whiteside TL. Immune responses to p53 in patients with cancer:enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 2005;54:1072-81. [DOI: 10.1007/s00262-005-0670-9] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 4.5] [Reference Citation Analysis]
110 Servidei T, Ferlini C, Riccardi A, Meco D, Scambia G, Segni G, Manzotti C, Riccardi R. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. European Journal of Cancer 2001;37:930-8. [DOI: 10.1016/s0959-8049(01)00061-2] [Cited by in Crossref: 66] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
111 Mo B, Pater A. Apoptosis, 5-fluorouracil sensitivity and expression of apoptotic proteins in a human ectocervical cell carcinogenesis model using different media. European Journal of Pharmacology 2003;467:15-22. [DOI: 10.1016/s0014-2999(03)01561-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
112 Alam S, Kelleher SL. Cellular mechanisms of zinc dysregulation: a perspective on zinc homeostasis as an etiological factor in the development and progression of breast cancer. Nutrients. 2012;4:875-903. [PMID: 23016122 DOI: 10.3390/nu4080875] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 7.9] [Reference Citation Analysis]
113 Greinert R, Breitbart EW, Volkmer B. UV-Radiation Biology as Part of Cancer Research. In: Kiefer J, editor. Life Sciences and Radiation. Berlin: Springer Berlin Heidelberg; 2004. pp. 139-55. [DOI: 10.1007/978-3-642-18687-5_12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
114 Hodorova I, Solar P, Mihalik J, Vecanova J, Adamkov M, Rybarova S. Investigation of tumour supressor protein p53 in renal cell carcinoma patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014;158:044-9. [DOI: 10.5507/bp.2012.035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
115 Burger H, Nooter K, Boersma AW, van Wingerden KE, Looijenga LH, Jochemsen AG, Stoter G. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer 1999;81:620-8. [DOI: 10.1002/(sici)1097-0215(19990517)81:4<620::aid-ijc19>3.0.co;2-s] [Cited by in Crossref: 57] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
116 Guimarães Tiezzi D, Moreira De Andrade J, José Cândido Dos Reis F, Ricardo Cosiski Marana H, Ribeiro-silva A, Guimarães Tiezzi M, Plácido Pereira A. Apoptosis induced by neoadjuvant chemotherapy in breast cancer. Pathology 2006;38:21-7. [DOI: 10.1080/00313020500465315] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
117 Hossian AKMN, Sajib MS, Tullar PE, Mikelis CM, Mattheolabakis G. Multipronged activity of combinatorial miR-143 and miR-506 inhibits Lung Cancer cell cycle progression and angiogenesis in vitro. Sci Rep 2018;8:10495. [PMID: 30002440 DOI: 10.1038/s41598-018-28872-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
118 Hussain SP, Hollstein MH, Harris CC. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Ann N Y Acad Sci. 2000;919:79-85. [PMID: 11083100 DOI: 10.1111/j.1749-6632.2000.tb06870.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
119 Ouhtit A, Nakazawa H, Yamasaki H, Armstrong BK, Kricker A, Tan E, English DR. UV-Radiation-Specific p53 Mutation Frequency in Normal Skin as a Predictor of Risk of Basal Cell Carcinoma. JNCI: Journal of the National Cancer Institute 1998;90:523-31. [DOI: 10.1093/jnci/90.7.523] [Cited by in Crossref: 50] [Cited by in F6Publishing: 291] [Article Influence: 2.1] [Reference Citation Analysis]
120 Majima T, Tsujiuchi T, Tsutsumi M, Tsunoda T, Konishi Y. Mutations of K-ras but not p53 genes in biliary duct and pancreatic duct carcinomas induced in hamsters by cholecystoduodenostomy with dissection of the common duct followed by N-nitrosobis(2-oxopropyl)amine. Cancer Letters 1997;118:47-53. [DOI: 10.1016/s0304-3835(97)00221-8] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
121 Bruix J, Llovet JM. Locoregional treatments for hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol. 1999;13:611-622. [PMID: 10654923 DOI: 10.1053/bega.1999.0051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
122 Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Lack of correlation between cisplatin-induced apoptosis,p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J Cancer 1997;73:592-9. [DOI: 10.1002/(sici)1097-0215(19971114)73:4<592::aid-ijc22>3.0.co;2-a] [Cited by in Crossref: 73] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
123 Minamoto T, Ronai Z. Gene mutation as a target for early detection in cancer diagnosis. Crit Rev Oncol Hematol 2001;40:195-213. [PMID: 11738944 DOI: 10.1016/s1040-8428(01)00098-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
124 Kaserer K, Schmaus J, Bethge U, Migschitz B, Fasching S, Walch A, Herbst F, Teleky B, Wrba F. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J Pathol 2000;190:450-6. [PMID: 10699994 DOI: 10.1002/(SICI)1096-9896(200003)190:4<450::AID-PATH545>3.0.CO;2-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
125 Dave B, Eason RR, Geng Y, Su Y, Badger TM, Simmen RC. Tp53-associated growth arrest and DNA damage repair gene expression is attenuated in mammary epithelial cells of rats fed whey proteins. J Nutr 2006;136:1156-60. [PMID: 16614397 DOI: 10.1093/jn/136.5.1156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
126 Hori M, Suzuki K, Udono MU, Yamauchi M, Mine M, Watanabe M, Kondo S, Hozumi Y. Establishment of ponasterone A-inducible the wild-type p53 protein-expressing clones from HSC-1 cells, cell growth suppression by p53 expression and the suppression mechanism. Arch Dermatol Res 2009;301:631-46. [PMID: 19009304 DOI: 10.1007/s00403-008-0915-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
127 Trong-Tue N, Thao DT, Yamaguchi M. Role of DREF in transcriptional regulation of the Drosophila p53 gene. Oncogene 2010;29:2060-9. [PMID: 20101238 DOI: 10.1038/onc.2009.483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
128 Lam SK, Ng TB. First report of a haemagglutinin-induced apoptotic pathway in breast cancer cells. Biosci Rep 2010;30:307-17. [PMID: 19689432 DOI: 10.1042/BSR20090059] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
129 Ljungman M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2000;2:208-25. [PMID: 10935507 DOI: 10.1038/sj.neo.7900073] [Cited by in Crossref: 135] [Cited by in F6Publishing: 135] [Article Influence: 6.1] [Reference Citation Analysis]
130 Kumar S, Diwan A, Singh P, Gulati S, Choudhary D, Mongia A, Shukla S, Gupta A. Functionalized gold nanostructures: promising gene delivery vehicles in cancer treatment. RSC Adv 2019;9:23894-907. [DOI: 10.1039/c9ra03608c] [Cited by in Crossref: 17] [Article Influence: 5.7] [Reference Citation Analysis]
131 Gleich LL. Gene Therapy for Head and Neck Cancer: . The Laryngoscope 2000;110:708-26. [DOI: 10.1097/00005537-200005000-00002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
132 Zunino F, Perego P, Pilotti S, Pratesi G, Supino R, Arcamone F. Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacology & Therapeutics 1997;76:177-85. [DOI: 10.1016/s0163-7258(97)00086-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
133 Ladiwala U, Li H, Antel JP, Nalbantoglu J. p53 induction by tumor necrosis factor-alpha and involvement of p53 in cell death of human oligodendrocytes. J Neurochem 1999;73:605-11. [PMID: 10428056 DOI: 10.1046/j.1471-4159.1999.0730605.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 1.7] [Reference Citation Analysis]
134 Wazer DE, Band V. Molecular and anatomic considerations in the pathogenesis of breast cancer. Radiat Oncol Investig 1999;7:1-12. [PMID: 10030618 DOI: 10.1002/(sici)1520-6823(1999)7:1<1::aid-roi1>3.0.co;2-i] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL. Combined modality radioimmunotherapy. Promise and peril. Cancer 2002;94:1320-31. [PMID: 11877763 DOI: 10.1002/cncr.10303] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
136 Winthrop MD, Denardo SJ, Muenzer JT, Chi S, Gumerlock PH. p53-independent response of a human breast carcinoma xenograft to radioimmunotherapy. Cancer 1997;80:2529-37. [DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2529::aid-cncr27>3.0.co;2-d] [Cited by in Crossref: 14] [Article Influence: 0.6] [Reference Citation Analysis]
137 Hosseinzadeh Colagar A, Amjadi Souraki O. Review of Pumpkin Anticancer Effects. Quran Med 2011;1:77-88. [DOI: 10.5812/quranmed.8923] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Adams SW, Emerson SG. GENE THERAPY FOR LEUKEMIA AND LYMPHOMA. Hematology/Oncology Clinics of North America 1998;12:631-48. [DOI: 10.1016/s0889-8588(05)70012-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
139 Mitra S, Varghese AC, Mandal S, Bhattacharyya S, Nandi P, Rahman SM, Kar KK, Saha R, Roychoudhury S, Murmu N. Lead and cadmium exposure induces male reproductive dysfunction by modulating the expression profiles of apoptotic and survival signal proteins in tea-garden workers. Reprod Toxicol 2020;98:134-48. [PMID: 32976933 DOI: 10.1016/j.reprotox.2020.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Pratesi G, Perego P, Polizzi D, Righetti SC, Supino R, Caserini C, Manzotti C, Giuliani FC, Pezzoni G, Tognella S, Spinelli S, Farrell N, Zunino F. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer 1999;80:1912-9. [PMID: 10471039 DOI: 10.1038/sj.bjc.6690620] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 3.6] [Reference Citation Analysis]
141 Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 2003;94:394-9. [PMID: 12824911 DOI: 10.1111/j.1349-7006.2003.tb01453.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
142 Spataro V, Norbury C, Harris AL. The ubiquitin-proteasome pathway in cancer. Br J Cancer 1998;77:448-55. [PMID: 9472642 DOI: 10.1038/bjc.1998.71] [Cited by in Crossref: 140] [Cited by in F6Publishing: 134] [Article Influence: 5.8] [Reference Citation Analysis]
143 Li Z, Xie J, Wu J, Li W, Nie L, Sun X, Tang A, Li X, Liu R, Mei H, Wang F, Wang Z, Gui Y, Cai Z. CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis. PLoS One 2014;9:e88965. [PMID: 24586462 DOI: 10.1371/journal.pone.0088965] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
144 Tascilar M, Sturm PD, Caspers E, Smit M, Polak MM, Huibregtse K, Noorduyn LA, Offerhaus GJA. Diagnostic p53 immunostaining of endobiliary brush cytology: Preoperative cytology compared with the surgical specimen. Cancer 1999;87:306-11. [DOI: 10.1002/(sici)1097-0142(19991025)87:5<306::aid-cncr11>3.0.co;2-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
145 Li Y, Yu X, Lou Y, Wang T. Rational Design of an Orthogonal Molecular Interaction System at the Complex Interface of Lung Cancer-Related MDM2 Protein with p53 Peptide. Aust J Chem 2016;69:1167. [DOI: 10.1071/ch16096] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
146 Lynch HT, Fusaro RM, Lynch JF. Cancer genetics in the new era of molecular biology. Ann N Y Acad Sci. 1997;833:1-28. [PMID: 9616736 DOI: 10.1111/j.1749-6632.1997.tb48588.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
147 Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 1999;187:8-18. [PMID: 10341702 DOI: 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y] [Cited by in Crossref: 115] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
148 Sabbatini P, McCormick F. MDMX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol 2002;21:519-25. [PMID: 12162806 DOI: 10.1089/104454902320219077] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
149 Hernández Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer 2021;1876:188556. [PMID: 33932560 DOI: 10.1016/j.bbcan.2021.188556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Berardi R, Maccaroni E, Onofri A, Giampieri R, Pistelli M, Bittoni A, Scartozzi M, Pierantoni C, Mandolesi A, Bearzi I, Cascinu S. Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. Expert Opin Pharmacother 2009;10:2467-78. [PMID: 19761354 DOI: 10.1517/14656560903143784] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
151 Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000;19:1245-56. [PMID: 10713666 DOI: 10.1038/sj.onc.1203434] [Cited by in Crossref: 270] [Cited by in F6Publishing: 260] [Article Influence: 12.3] [Reference Citation Analysis]
152 Deng J, Dayam R, Neamati N. Patented small molecule inhibitors of p53–MDM2 interaction. Expert Opinion on Therapeutic Patents 2006;16:165-88. [DOI: 10.1517/13543776.16.2.165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
153 Chène P. Influence of the N-terminal region on the oligomerisation between human and Xenopus laevis p53. Journal of Molecular Biology 1999;288:883-90. [DOI: 10.1006/jmbi.1999.2734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
154 Rana S, Gupta K, Gomez J, Matsuyama S, Chakrabarti A, Agarwal ML, Agarwal A, Agarwal MK, Wald DN. Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells. FASEB J. 2010;24:2126-2134. [PMID: 20133503 DOI: 10.1096/fj.09-148999] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
155 Chène P. p53 as a drug target in cancer therapy. Expert Opinion on Therapeutic Patents 2005;11:923-35. [DOI: 10.1517/13543776.11.6.923] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
156 Licitra L, Vermorken J. Is there still a role for neoadjuvant chemotherapy in head and neck cancer? Annals of Oncology 2004;15:7-11. [DOI: 10.1093/annonc/mdh001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
157 Novakovic P, Stempak JM, Sohn KJ, Kim YI. Effects of folate deficiency on gene expression in the apoptosis and cancer pathways in colon cancer cells. Carcinogenesis 2006;27:916-24. [PMID: 16361273 DOI: 10.1093/carcin/bgi312] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 3.8] [Reference Citation Analysis]
158 Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J 2000;19:370-8. [PMID: 10654936 DOI: 10.1093/emboj/19.3.370] [Cited by in Crossref: 116] [Cited by in F6Publishing: 108] [Article Influence: 5.3] [Reference Citation Analysis]
159 Yim EK, Lee KH, Bae JS, Namkoong SE, Um SJ, Park JS. Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. DNA Cell Biol 2004;23:769-76. [PMID: 15585135 DOI: 10.1089/dna.2004.23.769] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
160 Donninger H, Binder A, Bohm L, Parker MI. Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells. Biol Chem 2008;389:57-67. [PMID: 18095870 DOI: 10.1515/BC.2008.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
161 Zwahlen D, Tschan MP, Grob TJ, Peters UR, Fink D, Haenggi W, Altermatt HJ, Cajot J, Tobler A, Fey MF, Aebi S. Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours. Int J Cancer 2000;88:66-70. [DOI: 10.1002/1097-0215(20001001)88:1<66::aid-ijc10>3.0.co;2-y] [Cited by in Crossref: 26] [Article Influence: 1.2] [Reference Citation Analysis]
162 Powolny A, Xu J, Loo G. Deoxycholate induces DNA damage and apoptosis in human colon epithelial cells expressing either mutant or wild-type p53. Int J Biochem Cell Biol. 2001;33:193-203. [PMID: 11240376 DOI: 10.1016/s1357-2725(00)00080-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
163 Hussain RM, Matthews JL, Dubovy SR, Thompson JM, Wang G. UV-Independent p53 Mutations in Sebaceous Carcinoma of the Eyelid. Ophthalmic Plastic & Reconstructive Surgery 2014;30:392-5. [DOI: 10.1097/iop.0000000000000121] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
164 Sisk EA, Soltys SG, Zhu S, Fisher SG, Carey TE, Bradford CR. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 2002;24:841-9. [DOI: 10.1002/hed.10146] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 3.8] [Reference Citation Analysis]
165 Metcalfe A, Streuli C. Epithelial apoptosis. Bioessays 1997;19:711-20. [DOI: 10.1002/bies.950190812] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 1.6] [Reference Citation Analysis]
166 Mirjolet JF, Barberi-Heyob M, Didelot C, Peyrat JP, Abecassis J, Millon R, Merlin JL. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer 2000;83:1380-6. [PMID: 11044365 DOI: 10.1054/bjoc.2000.1455] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 2.2] [Reference Citation Analysis]
167 Shostak S. Translating at Work: Genetically Modified Mouse Models and Molecularization in the Environmental Health Sciences. Science, Technology, & Human Values 2007;32:315-38. [DOI: 10.1177/0162243906298353] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
168 Nikitina EY, Chada S, Muro-Cacho C, Fang B, Zhang R, Roth JA, Gabrilovich DI. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther 2002;9:345-52. [PMID: 11938454 DOI: 10.1038/sj.gt.3301670] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
169 Scopa CD, Vagianos C, Kardamakis D, Kourelis TG, Kalofonos HP, Tsamandas AC. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol 2001;9:329-34. [PMID: 11759059 DOI: 10.1097/00129039-200112000-00007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 0.8] [Reference Citation Analysis]
170 Buolamwini JK. Novel Molecular Targets for Cancer Drug Discovery. In: Coleman WB, Tsongalis GJ, editors. The Molecular Basis of Human Cancer. Totowa: Humana Press; 2002. pp. 521-40. [DOI: 10.1007/978-1-59259-125-1_23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
171 Osada H, Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 2002;21:7421-34. [DOI: 10.1038/sj.onc.1205802] [Cited by in Crossref: 144] [Cited by in F6Publishing: 108] [Article Influence: 7.2] [Reference Citation Analysis]
172 Ciftci G, Aksoy A, Cenesiz S, Sogut MU, Yarim GF, Nisbet C, Guvenc D, Ertekin A. Therapeutic role of curcumin in oxidative DNA damage caused by formaldehyde. Microsc Res Tech 2015;78:391-5. [PMID: 25761397 DOI: 10.1002/jemt.22485] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
173 Jeong JH, Nakajima H, Magae J, Furukawa C, Taki K, Otsuka K, Tomita M, Lee IS, Kim CH, Chang HW, Min KS, Park KK, Park KK, Chang YC. Ascochlorin activates p53 in a manner distinct from DNA damaging agents. Int J Cancer 2009;124:2797-803. [PMID: 19253369 DOI: 10.1002/ijc.24259] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
174 Marchenko ND, Zaika A, Moll UM. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem. 2000;275:16202-16212. [PMID: 10821866 DOI: 10.1074/jbc.275.21.16202] [Cited by in Crossref: 602] [Cited by in F6Publishing: 617] [Article Influence: 27.4] [Reference Citation Analysis]
175 Sakakura K, Chikamatsu K, Shino M, Sakurai T, Furuya N. Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma: possible markers as predictors of clinical outcome. Acta Otolaryngol 2006;126:1295-302. [PMID: 17101591 DOI: 10.1080/00016480600606624] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
176 Sander CS, Chang H, Hamm F, Elsner P, Thiele JJ. Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int J Dermatol 2004;43:326-35. [DOI: 10.1111/j.1365-4632.2004.02222.x] [Cited by in Crossref: 298] [Cited by in F6Publishing: 269] [Article Influence: 16.6] [Reference Citation Analysis]
177 Dunnick JK, Hardisty JF, Herbert RA, Seely JC, Furedi-machacek EM, Foley JF, Lacks GD, Stasiewicz S, French JE. Phenolphthalein Induces Thymic Lymphomas Accompanied by Loss of the p53 Wild Type Allele in Heterozygous p53-Deficient (±) Mice. Toxicol Pathol 1997;25:533-40. [DOI: 10.1177/019262339702500601] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 8.5] [Reference Citation Analysis]
178 Adler V, Pincus MR, Minamoto T, Fuchs SY, Bluth MJ, Brandt-Rauf PW, Friedman FK, Robinson RC, Chen JM, Wang XW, Harris CC, Ronai Z. Conformation-dependent phosphorylation of p53. Proc Natl Acad Sci U S A 1997;94:1686-91. [PMID: 9050839 DOI: 10.1073/pnas.94.5.1686] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 3.6] [Reference Citation Analysis]
179 Bennett L, Wiseman RW. Mouse models for breast cancer susceptibility. Environmental Toxicology and Pharmacology 1997;4:283-8. [DOI: 10.1016/s1382-6689(97)10024-2] [Reference Citation Analysis]
180 Ecke TH, Schlechte HH, Gunia S, Lenk SV, Loening SA. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer. Urologic Oncology: Seminars and Original Investigations 2008;26:470-3. [DOI: 10.1016/j.urolonc.2007.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
181 Takenoshita S, Mogi A, Nagashima M, Yang K, Yagi K, Hanyu A, Nagamachi Y, Miyazono K, Hagiwara K. Characterization of theMADH2/Smad2Gene, a HumanMadHomolog Responsible for the Transforming Growth Factor-β and Activin Signal Transduction Pathway. Genomics 1998;48:1-11. [DOI: 10.1006/geno.1997.5149] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 1.6] [Reference Citation Analysis]
182 Takahashi M, Tonoki H, Tada M, Kashiwazaki H, Furuuchi K, Hamada J, Fujioka Y, Sato Y, Takahashi H, Todo S, Sakuragi N, Moriuchi T. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 2000;89:92-9. [PMID: 10719737 DOI: 10.1002/(sici)1097-0215(20000120)89:1<92::aid-ijc15>3.0.co;2-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
183 Niu Y, Xie W, Qin W. Molecular mechanism for the involvement of nuclear receptor FXR in HBV-associated hepatocellular carcinoma. Acta Pharmaceutica Sinica B 2011;1:73-9. [DOI: 10.1016/j.apsb.2011.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
184 Kim YI, Shirwadkar S, Choi SW, Puchyr M, Wang Y, Mason JB. Effects of dietary folate on DNA strand breaks within mutation-prone exons of the p53 gene in rat colon. Gastroenterology 2000;119:151-61. [PMID: 10889164 DOI: 10.1053/gast.2000.8518] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 2.9] [Reference Citation Analysis]
185 Szumilo J, Chibowski D, Dabrowski A. Assessment of the predictive value of clinical and histopathological factors as well as the immunoexpression of p53 and bcl-2 proteins in response to preoperative chemotherapy for esophageal squamous cell carcinoma. Dis Esophagus 2000;13:191-7. [DOI: 10.1046/j.1442-2050.2000.00110.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
186 Brachmann RK, Yu K, Eby Y, Pavletich NP, Boeke JD. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J 1998;17:1847-59. [PMID: 9524109 DOI: 10.1093/emboj/17.7.1847] [Cited by in Crossref: 120] [Cited by in F6Publishing: 114] [Article Influence: 5.0] [Reference Citation Analysis]
187 Zhou YM, Cao L, Li B, Zhang XZ, Yin ZF. Expression of HBx protein in hepatitis B virus-infected intrahepatic cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2012;11:532-535. [PMID: 23060400 DOI: 10.1016/s1499-3872(12)60219-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
188 Costello JF, Plass C. Methylation matters. J Med Genet. 2001;38:285-303. [PMID: 11333864 DOI: 10.1136/jmg.38.5.285] [Cited by in Crossref: 345] [Cited by in F6Publishing: 315] [Article Influence: 16.4] [Reference Citation Analysis]
189 Hammel P, Soussi T. Serum p53 antibody assay: evaluation in colorectal cancer. Rev Med Interne. 2000;21:167-173. [PMID: 10703073 DOI: 10.1016/S0248-8663(00)88246-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
190 Griewe GL, Dean RC, Zhang W, Young D, Sesterhenn IA, Shanmugam N, McLeod DG, Moul JW, Srivastava S. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. Prostate Cancer Prostatic Dis 2003;6:281-5. [PMID: 14663467 DOI: 10.1038/sj.pcan.4500665] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
191 Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, Yamazaki M, Ito K, Nagamatsu M, Nishizaki T, Asada M, Kameda T, Wakimoto A, Mizutani T, Yamada T, Murata Y. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett 2006;241:289-300. [PMID: 16459017 DOI: 10.1016/j.canlet.2005.10.035] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
192 Real PJ, Sanz C, Gutierrez O, Pipaon C, Zubiaga AM, Fernandez-Luna JL. Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. FEBS Lett 2006;580:5905-9. [PMID: 17027756 DOI: 10.1016/j.febslet.2006.08.088] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
193 Wang YC, Lee HS, Chen SK, Chang YY, Chen CY. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer. 1999;35:226-230. [PMID: 10448264 DOI: 10.1016/s0959-8049(98)00369-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
194 Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol. 2003;14:1026-1038. [PMID: 12853343 DOI: 10.1093/annonc/mdg284] [Cited by in Crossref: 88] [Cited by in F6Publishing: 81] [Article Influence: 4.6] [Reference Citation Analysis]
195 van Oijen MG, van de Craats JG, Slootweg PJ. p53 overexpression in oral mucosa in relation to smoking. J Pathol 1999;187:469-74. [PMID: 10398108 DOI: 10.1002/(SICI)1096-9896(199903)187:4<469::AID-PATH262>3.0.CO;2-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
196 Ford JH. Saturated fatty acid metabolism is key link between cell division, cancer, and senescence in cellular and whole organism aging. Age (Dordr) 2010;32:231-7. [PMID: 20431990 DOI: 10.1007/s11357-009-9128-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
197 Marugan JJ, Leonard K, Raboisson P, Gushue JM, Calvo R, Koblish HK, Lattanze J, Zhao S, Cummings MD, Player MR, Schubert C, Maroney AC, Lu T. Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists. Bioorganic & Medicinal Chemistry Letters 2006;16:3115-20. [DOI: 10.1016/j.bmcl.2006.03.067] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
198 Nygren P, Csòka K, Larsson R, Busch C, Wester K, Malmström P. ACTIVITY OF STANDARD AND INVESTIGATIONAL CYTOTOXIC DRUGS IN PRIMARY CULTURES OF TUMOR CELLS FROM PATIENTS WITH KIDNEY AND URINARY BLADDER CARCINOMAS. Journal of Urology 1999;162:2200-4. [DOI: 10.1016/s0022-5347(05)68159-1] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
199 Brodowicz T, Kandioler D, Tomek S, Ludwig C, Rudas M, Kunstfeld R, Koestler W, Hejna M, Budinsky A, Wiltschke C, Zielinski CC. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status. Br J Cancer 2001;85:1764-70. [PMID: 11742500 DOI: 10.1054/bjoc.2001.2197] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
200 Biroš E, Kohút A, Biroš I, Kalina I, Bogyiová E, Štubňa J. A link between the p53 germ line polymorphisms and white blood cells apoptosis in lung cancer patients. Lung Cancer 2002;35:231-5. [DOI: 10.1016/s0169-5002(01)00446-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
201 Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M. VACCINIA VIRUS MEDIATED p53 GENE THERAPY FOR BLADDER CANCER IN AN ORTHOTOPIC MURINE MODEL. Journal of Urology 2005;173:604-9. [DOI: 10.1097/01.ju.0000143196.37008.2c] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
202 Butel JS. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 2000;21:405-26. [PMID: 10688861 DOI: 10.1093/carcin/21.3.405] [Cited by in Crossref: 217] [Cited by in F6Publishing: 191] [Article Influence: 9.9] [Reference Citation Analysis]
203 Daidone MG, Benini E, Rao S, Pilotti S, Silvestrini R. Fixation Time and Microwave Oven Irradiation Affect Immunocytochemical p53 Detection in Formalin-Fixed Paraffin Sections: . Applied Immunohistochemistry 1998;6:140-4. [DOI: 10.1097/00022744-199809000-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
204 Cascinu S, Graziano F, Ferro ED, Staccioli MP, Ligi M, Carnevali A, Muretto P, Catalano G. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998;83:1917-22. [DOI: 10.1002/(sici)1097-0142(19981101)83:9<1917::aid-cncr6>3.0.co;2-1] [Cited by in Crossref: 49] [Article Influence: 2.0] [Reference Citation Analysis]
205 deVere White RW, Deitch AD, Gumerlock PH, Shi X. Use of a yeast assay to detect functional alterations inp53 in prostate cancer: Review and future directions. Prostate 1999;41:134-42. [DOI: 10.1002/(sici)1097-0045(19991001)41:2<134::aid-pros8>3.0.co;2-e] [Cited by in Crossref: 10] [Article Influence: 0.4] [Reference Citation Analysis]
206 Colomer A, Erill N, Verdú M, Roman R, Vidal A, Cordon-cardo C, Puig X. Lack of p53 Nuclear Immunostaining Is Not Indicative of Absence of TP53 Gene Mutations in Colorectal Adenocarcinomas: . Applied Immunohistochemistry & Molecular Morphology 2003;11:130-7. [DOI: 10.1097/00129039-200306000-00007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
207 Hussain S, Hofseth LJ, Harris CC. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 2001;34:S7-S15. [DOI: 10.1016/s0169-5002(01)00339-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
208 Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AK. p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang. Am J Obstet Gynecol 2001;184:891-902; discussion 902-3. [PMID: 11303196 DOI: 10.1067/mob.2001.113856] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
209 Sze DY, Freeman SM, Slonim SM, Samuels SL, Andrews JC, Hicks M, Ahrar K, Gupta S, Reid TR. Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J Vasc Interv Radiol. 2003;14:279-290. [PMID: 12631632 DOI: 10.1097/01.rvi.0000058422.01661.1e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
210 Gallagher W, Brown R. p53-Oriented cancer therapies: Current progress. Annals of Oncology 1999;10:139-50. [DOI: 10.1023/a:1008368500557] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
211 Kamoshida S, Suzuki M, Shimomura R, Sakurai Y, Komori Y, Uyama I, Tsutsumi Y. Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Br J Cancer 2007;96:277-83. [PMID: 17211470 DOI: 10.1038/sj.bjc.6603546] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
212 Raspollini M, Taddei G. Tumor markers in ovarian carcinoma. International Journal of Gynecology & Obstetrics 2007;97:175-81. [DOI: 10.1016/j.ijgo.2007.02.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
213 Céraline J, Deplanque G, Duclos B, Limacher J, Hajri A, Noel F, Orvain C, Frébourg T, Klein-soyer C, Bergerat J. Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents. Int J Cancer 1998;75:432-8. [DOI: 10.1002/(sici)1097-0215(19980130)75:3<432::aid-ijc17>3.0.co;2-a] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
214 Lang FF, Yung WKA, Raju U, Libunao F, Terry NHA, Tofilon PJ. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. Journal of Neurosurgery 1998;89:125-32. [DOI: 10.3171/jns.1998.89.1.0125] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 2.5] [Reference Citation Analysis]
215 Oh SJ, Ju J, Kim BC, Ko E, Hong BJ, Park JG, Park JW, Choi KY. DNA microarrays on a dendron-modified surface improve significantly the detection of single nucleotide variations in the p53 gene. Nucleic Acids Res 2005;33:e90. [PMID: 15939931 DOI: 10.1093/nar/gni087] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
216 Khan SA, Thomas HC, Toledano MB, Cox IJ, Taylor-Robinson SD. p53 Mutations in human cholangiocarcinoma: a review. Liver Int. 2005;25:704-716. [PMID: 15998419 DOI: 10.1111/j.1478-3231.2005.01106.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
217 Ahrendt SA, Hu Y, Buta M, Mcdermott MP, Benoit N, Yang SC, Wu L, Sidransky D. p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study. JNCI Journal of the National Cancer Institute 2003;95:961-70. [DOI: 10.1093/jnci/95.13.961] [Cited by in Crossref: 145] [Cited by in F6Publishing: 120] [Article Influence: 7.6] [Reference Citation Analysis]
218 Lu-hesselmann J, van Beuningen D, Meineke V, Franke E. Influences of TP53 expression on cellular radiation response and its relevance to diagnostic biodosimetry for mission environmental monitoring. Radiation Protection Dosimetry 2006;122:237-43. [DOI: 10.1093/rpd/ncl459] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
219 Tjalma WA, Weyler JJ, Bogers JJ, Pollefliet C, Baay M, Goovaerts GC, Vermorken JB, van Dam PA, van Marck EA, Buytaert PM. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology 2001;97:223-30. [DOI: 10.1016/s0301-2115(00)00541-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
220 Dworakowska D, Jassem E, Jassem J, Karmoliński A, Dworakowski R, Wirth T, Gruchała M, Rynkiewicz A, Skokowski J, Yla-herttuala S, Jaśkiewicz K, Częstochowska E. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression. J Cancer Res Clin Oncol 2005;131:617-23. [DOI: 10.1007/s00432-005-0010-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
221 Fujiwara T, Kataoka M, Tanaka N. Adenovirus-mediated p53 gene therapy for human cancer. Mol Urol. 2000;4:51-54. [PMID: 12006242 DOI: 10.1089/10915360050138585] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
222 O'donnell RT, Denardo SJ, Denardo GL, Miers L, Lamborn KR, Kukis DL, Meyers FJ. Efficacy and toxicity of radioimmunotherapy with90Y-DOTA-peptide-ChL6 for PC3-tumored mice. Prostate 2000;44:187-92. [DOI: 10.1002/1097-0045(20000801)44:3<187::aid-pros2>3.0.co;2-c] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
223 Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-88. [DOI: 10.1053/j.gastro.2004.09.032] [Cited by in Crossref: 369] [Cited by in F6Publishing: 337] [Article Influence: 20.5] [Reference Citation Analysis]
224 Cheng L, Sebo TJ, Cheville JC, Pisansky TM, Slezak J, Bergstralh EJ, Pacelli A, Neumann RM, Zincke H, Bostwick DG. p53 Protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer 1999;85:1293-9. [DOI: 10.1002/(sici)1097-0142(19990315)85:6<1293::aid-cncr11>3.0.co;2-o] [Cited by in Crossref: 45] [Article Influence: 2.0] [Reference Citation Analysis]
225 Burger H, Nooter K, Boersma AW, Kortland CJ, van den Berg AP, Stoter G. Expression of p53, p21/WAF/CIP, Bcl-2, Bax, Bcl-x, and Bak in radiation-induced apoptosis in testicular germ cell tumor lines. Int J Radiat Oncol Biol Phys. 1998;41:415-424. [PMID: 9607360 DOI: 10.1016/s0360-3016(98)00065-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
226 Janiec-jankowska A, Konopka B, Goluda C, Najmoła U. TP53 Mutations in Endometrial Cancers: Relation to PTEN Gene Defects. International Journal of Gynecological Cancer 2010;20:196-202. [DOI: 10.1111/igc.0b013e3181c83675] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
227 Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies: Clonality of Multifocal Urothelial Carcinomas. Int J Cancer 2002;101:1-6. [DOI: 10.1002/ijc.10544] [Cited by in Crossref: 127] [Cited by in F6Publishing: 100] [Article Influence: 6.4] [Reference Citation Analysis]
228 Vaughan TL. Esophagus. In: Franco EL, Rohan TE, editors. Cancer Precursors. New York: Springer-Verlag; 2002. pp. 96-116. [DOI: 10.1007/0-387-21605-7_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
229 Fallai C, Perrone F, Licitra L, Pilotti S, Locati L, Bossi P, Orlandi E, Palazzi M, Olmi P. Oropharyngeal Squamous Cell Carcinoma Treated With Radiotherapy or Radiochemotherapy: Prognostic Role of TP53 and HPV Status. International Journal of Radiation Oncology*Biology*Physics 2009;75:1053-9. [DOI: 10.1016/j.ijrobp.2008.12.088] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
230 Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 2001;84:1052-7. [PMID: 11308253 DOI: 10.1054/bjoc.2000.1715] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 1.6] [Reference Citation Analysis]
231 Wen W, Che W, Lu L, Yang J, Gao X, Wen J, Heng Z, Cao S, Cheng H. Increased damage of exon 5 of p53 gene in workers from an arsenic plant. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2008;643:36-40. [DOI: 10.1016/j.mrfmmm.2008.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
232 Keohavong P, Lan Q, Gao W. p53 and K-ras mutations in lung tissues and sputum samples of individuals exposed to smoky coal emissions in Xuan Wei County, China. Mutat Res Genet Toxicol Environ Mutagen 2018;829-830:70-4. [PMID: 29704996 DOI: 10.1016/j.mrgentox.2018.03.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
233 Zainuddin N, Berglund M, Wanders A, Ren Z, Amini R, Lindell M, Kanduri M, Roos G, Rosenquist R, Enblad G. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leukemia Research 2009;33:60-6. [DOI: 10.1016/j.leukres.2008.06.022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
234 Neal C, Garcea G, Doucas H, Manson M, Sutton C, Dennison A, Berry D. Molecular prognostic markers in resectable colorectal liver metastases: A systematic review. European Journal of Cancer 2006;42:1728-43. [DOI: 10.1016/j.ejca.2006.01.056] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
235 Sohn KJ, Smirnakis F, Moskovitz DN, Novakovic P, Yates Z, Lucock M, Croxford R, Kim YI. Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. Gut 2004;53:1825-31. [PMID: 15542523 DOI: 10.1136/gut.2004.042713] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
236 Cheng J, Hui M, Sha Z. Transcriptomic analysis reveals insights into deep-sea adaptations of the dominant species, Shinkaia crosnieri (Crustacea: Decapoda: Anomura), inhabiting both hydrothermal vents and cold seeps. BMC Genomics 2019;20:388. [PMID: 31103028 DOI: 10.1186/s12864-019-5753-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
237 Prescott J, Patel H, Tillman S, Mchugh T, Ralph D. Cleavage of double-stranded copy RNA by RNase 1 and RNase T 1 provides a robust means to detectp53 gene mutations in clinical specimens. Electrophoresis 1999;20:1149-61. [DOI: 10.1002/(sici)1522-2683(19990101)20:6<1149::aid-elps1149>3.0.co;2-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
238 Mirbaha H, Carrillo D, Mitui M, Hiemenz MC, Singh V, Rakheja D. Cytoplasmic P53 Immunostaining With N-Terminus P53 Antibody And Absence Of Staining With C-Terminus P53 Antibody: A Report Of Two Pediatric Sarcomas With Distal Truncating TP53 Mutations Affecting Nuclear Localization Domain. Int J Surg Pathol. [DOI: 10.1177/10668969211065115] [Reference Citation Analysis]
239 Ceccaroni M, Chieco P, Alboni C, De Iaco P, Pagano K, Ceccarelli C, Santini D, Taroni B, Pelusi G. P53 Expression, Dna Ploidy and Mitotic Index as Prognostic Factors in Patients with Epithelial Ovarian Carcinoma. Tumori 2004;90:600-6. [DOI: 10.1177/030089160409000612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
240 Yoshino A, Katayama Y, Yokoyama T, Watanabe T, Ogino A, Ota T, Komine C, Fukushima T, Kusama K. Therapeutic Implications of Interferon Regulatory Factor (IRF)-1 and IRF-2 in Diffusely Infiltrating Astrocytomas (DIA): Response to Interferon (IFN)-β in Glioblastoma Cells and Prognostic Value for DIA. J Neurooncol 2005;74:249-60. [DOI: 10.1007/s11060-004-7316-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
241 Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA, Altermatt HJ, Schlaifer D, Reed JC, Betticher DC. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 1999;79:952-8. [PMID: 10070896 DOI: 10.1038/sj.bjc.6690152] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 2.7] [Reference Citation Analysis]
242 Gómez-Angelats M, Teeguarden JG, Dragan YP, Pitot HC. Mutational analysis of three tumor suppressor genes in two models of rat hepatocarcinogenesis. Mol Carcinog 1999;25:157-63. [PMID: 10411141 DOI: 10.1002/(sici)1098-2744(199907)25:3<157::aid-mc1>3.0.co;2-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
243 Suzuki H, Kawaguchi T, Hasegawa T, Yonechi A, Ohsugi J, Higuchi M, Yamada F, Shio Y, Fujiu K, Kanno R, Ohishi A, Gotoh M. Prognostic impact of p53 protein overexpression in patients with node-negative lung adenocarcinoma. Cancer Letters 2006;237:242-7. [DOI: 10.1016/j.canlet.2005.06.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
244 Kolfschoten G, Hulscher T, Schrier S, van Houten V, Pinedo H, Boven E. Time-Dependent Changes in Factors Involved in the Apoptotic Process in Human Ovarian Cancer Cells as a Response to Cisplatin. Gynecologic Oncology 2002;84:404-12. [DOI: 10.1006/gyno.2001.6537] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
245 Valenzuela MT, Mateos S, Ruiz de Almodóvar J, Mcmillan TJ. Variation in sensitizing effect of caffeine in human tumour cell lines after γ-irradiation. Radiotherapy and Oncology 2000;54:261-71. [DOI: 10.1016/s0167-8140(99)00180-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
246 Tchou-Wong KM, Jiang Y, Yee H, LaRosa J, Lee TC, Pellicer A, Jagirdar J, Gordon T, Goldberg JD, Rom WN. Lung-specific expression of dominant-negative mutant p53 in transgenic mice increases spontaneous and benzo(a)pyrene-induced lung cancer. Am J Respir Cell Mol Biol 2002;27:186-93. [PMID: 12151310 DOI: 10.1165/ajrcmb.27.2.4799] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
247 Casson AG. Role of molecular biology in the follow-up of patients who have Barrett's esophagus. Chest Surgery Clinics of North America 2002;12:93-111. [DOI: 10.1016/s1052-3359(03)00068-1] [Cited by in Crossref: 13] [Article Influence: 0.7] [Reference Citation Analysis]
248 Etienne MC, Pivot X, Formento JL, Bensadoun RJ, Formento P, Dassonville O, Francoual M, Poissonnet G, Fontana X, Schneider M, Demard F, Milano G. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 1999;79:1864-9. [PMID: 10206306 DOI: 10.1038/sj.bjc.6690297] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
249 Casson AG, Williams L, Guernsey DL. Epidemiology and molecular biology of Barrett esophagus. Semin Thorac Cardiovasc Surg. 2005;17:284-291. [PMID: 16428034 DOI: 10.1053/j.semtcvs.2005.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
250 D’atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J. Involvement of the Mismatch Repair System in Temozolomide-Induced Apoptosis. Mol Pharmacol 1998;54:334-41. [DOI: 10.1124/mol.54.2.334] [Cited by in Crossref: 159] [Cited by in F6Publishing: 155] [Article Influence: 6.6] [Reference Citation Analysis]
251 Chomehai JS, Du W, Sarkar FH, Li YW, Jacobs JR, Ensley JF, Sakr W, Yoo GH. Prognostic significance of p53 gene mutations in laryngeal cancer. Laryngoscope 1999;109:455-9. [DOI: 10.1097/00005537-199903000-00021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
252 Kouraklis G. Progress in cancer gene therapy. Acta Oncol. 1999;38:675-683. [PMID: 10522756 DOI: 10.1080/028418699432815] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis]
253 Koga F, Kitahara S, Arai K, Honda M, Sumi S, Yoshida K. Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer. Jpn J Cancer Res 2000;91:416-23. [PMID: 10804290 DOI: 10.1111/j.1349-7006.2000.tb00961.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
254 Kim AL, Athar M, Bickers DR, Gautier J. Stage-specific Alterations of Cyclin Expression During UVB-induced Murine Skin Tumor Development¶. Photochem Photobiol 2002;75:58. [DOI: 10.1562/0031-8655(2002)075<0058:ssaoce>2.0.co;2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
255 Perrotte P, Wood M, Slaton JW, Wilson DR, Pagliaro L, Price RE, Dinney CP. Biosafety of in vivo adenovirus-p53 intravesical administration in mice. Urology 2000;56:155-9. [DOI: 10.1016/s0090-4295(00)00537-9] [Cited by in Crossref: 18] [Article Influence: 0.8] [Reference Citation Analysis]
256 Jamiyandorj U, Bae JS, Noh SJ, Jachin S, Choi JE, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS. Expression of peptidyl-prolyl isomerase PIN1 and its role in the pathogenesis of extrahepatic cholangiocarcinoma. Oncol Lett 2013;6:1421-6. [PMID: 24179535 DOI: 10.3892/ol.2013.1525] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
257 Kamoshida S, Matsuoka H, Shiogama K, Matsuyama A, Shimomura R, Inada K, Maruta M, Tsutsumi Y. Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil. Pathol Int 2004;54:564-75. [PMID: 15260847 DOI: 10.1111/j.1440-1827.2004.01665.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
258 Bossi G, Mazzaro G, Porrello A, Crescenzi M, Soddu S, Sacchi A. Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene 2004;23:418-25. [PMID: 14724570 DOI: 10.1038/sj.onc.1207042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
259 Santini S, Bizzarri AR, Cannistraro S. Modelling the interaction between the p53 DNA-binding domain and the p28 peptide fragment of Azurin: MODELLING OF THE COMPLEX BETWEEN DBD OF P53 AND THE P28 PEPTIDE. J Mol Recognit 2011;24:1043-55. [DOI: 10.1002/jmr.1153] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
260 Paramio JM, Segrelles C, Laín S, Gómez-Casero E, Lane DP, Lane EB, Jorcano JL. p53 is phosphorylated at the carboxyl terminus and promotes the differentiation of human HaCaT keratinocytes. Mol Carcinog 2000;29:251-62. [PMID: 11170263 DOI: 10.1002/1098-2744(200012)29:4<251::aid-mc1007>3.0.co;2-o] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
261 Ng CE, Qutob S, Pavliv M, Lamarche P, Mao J, Peter Raaphorst G. Hsp 27 is better associated with the expression of inducible thermotolerance in human pancreatic tumor cell lines than hsp 70, p53 or p21/waf1/cip1. Journal of Thermal Biology 2002;27:47-54. [DOI: 10.1016/s0306-4565(01)00014-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
262 Newton HB. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle. Expert Rev Anticancer Ther 2005;5:355-78. [PMID: 15877531 DOI: 10.1586/14737140.5.2.355] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
263 Galle PR. Apoptosis in liver disease. Journal of Hepatology 1997;27:405-12. [DOI: 10.1016/s0168-8278(97)80189-4] [Cited by in Crossref: 78] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
264 Nagata Y, Anan T, Yoshida T, Mizukami T, Taya Y, Fujiwara T, Kato H, Saya H, Nakao M. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association. Oncogene. 1999;18:6037-6049. [PMID: 10557093 DOI: 10.1038/sj.onc.1202978] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 3.2] [Reference Citation Analysis]
265 Sengupta S, Vonesch JL, Waltzinger C, Zheng H, Wasylyk B. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J 2000;19:6051-64. [PMID: 11080152 DOI: 10.1093/emboj/19.22.6051] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 3.4] [Reference Citation Analysis]
266 Aoki S, Kong D, Matsui K, Kobayashi M. Smenospongine, a spongean sesquiterpene aminoquinone, induces erythroid differentiation in K562 cells: . Anti-Cancer Drugs 2004;15:363-9. [DOI: 10.1097/00001813-200404000-00009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
267 Barbaric D, Stevens M, Dalla-Pozza L. Neurofibromatosis type 1 and multiple primary malignancies. Med Pediatr Oncol 2003;41:568-9. [PMID: 14595719 DOI: 10.1002/mpo.10423] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
268 Krauss P, Zankl A, Schilling A, Schulze H, Metzner C. Analysis of Structure and Dynamics in Three-Neuron Motifs. Front Comput Neurosci 2019;13:5. [PMID: 30792635 DOI: 10.3389/fncom.2019.00005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
269 Matter B, Guza R, Zhao J, Li Z, Jones R, Tretyakova N. Sequence Distribution of Acetaldehyde-Derived N2 -Ethyl-dG Adducts along Duplex DNA. Chem Res Toxicol 2007;20:1379-87. [DOI: 10.1021/tx7001146] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
270 Thamkachy R, Kumar R, Rajasekharan KN, Sengupta S. ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells. Mol Cancer 2016;15:22. [PMID: 26956619 DOI: 10.1186/s12943-016-0505-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
271 Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, Andreeff M. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005;106:3150-9. [PMID: 16014563 DOI: 10.1182/blood-2005-02-0553] [Cited by in Crossref: 262] [Cited by in F6Publishing: 236] [Article Influence: 15.4] [Reference Citation Analysis]
272 Vaseva AV, Moll UM. Identification of p53 in mitochondria. Methods Mol Biol 2013;962:75-84. [PMID: 23150438 DOI: 10.1007/978-1-62703-236-0_6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
273 Wenande E, Tam J, Bhayana B, Schlosser SK, Ishak E, Farinelli WA, Chlopik A, Hoang MP, Pinkhasov OR, Caravan P, Rox Anderson R, Haedersdal M. Laser-assisted delivery of synergistic combination chemotherapy in in vivo skin. Journal of Controlled Release 2018;275:242-53. [DOI: 10.1016/j.jconrel.2018.02.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
274 Abd Eldaim MA, Tousson E, Soliman MM, El Sayed IET, Abdel Aleem AAH, Elsharkawy HN. Grape seed extract ameliorated Ehrlich solid tumor-induced hepatic tissue and DNA damage with reduction of PCNA and P53 protein expression in mice. Environ Sci Pollut Res Int 2021;28:44226-38. [PMID: 33851294 DOI: 10.1007/s11356-021-13904-8] [Reference Citation Analysis]
275 Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Anders RA, Gao ZH. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis. Histopathology 2010;56:683-93. [PMID: 20546333 DOI: 10.1111/j.1365-2559.2010.03554.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
276 Khan MM, Rydén AM, Chowdhury MS, Hasan MA, Kazi JU. Maximum likelihood analysis of mammalian p53 indicates the presence of positively selected sites and higher tumorigenic mutations in purifying sites. Gene 2011;483:29-35. [PMID: 21640173 DOI: 10.1016/j.gene.2011.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
277 Lawinger P, Venugopal R, Guo ZS, Immaneni A, Sengupta D, Lu W, Rastelli L, Marin Dias Carneiro A, Levin V, Fuller GN, Echelard Y, Majumder S. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nat Med 2000;6:826-31. [PMID: 10888935 DOI: 10.1038/77565] [Cited by in Crossref: 125] [Cited by in F6Publishing: 125] [Article Influence: 5.7] [Reference Citation Analysis]
278 Hwang RF, Hunt KK. Experimental approaches to treatment of soft tissue sarcoma. Surg Oncol Clin N Am 2003;12:499-521. [PMID: 12916466 DOI: 10.1016/s1055-3207(03)00006-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
279 Huang C, Ma WY, Maxiner A, Sun Y, Dong Z. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J Biol Chem 1999;274:12229-35. [PMID: 10212189 DOI: 10.1074/jbc.274.18.12229] [Cited by in Crossref: 211] [Cited by in F6Publishing: 204] [Article Influence: 9.2] [Reference Citation Analysis]
280 Taubert H, Meye A, Würl P. Soft Tissue Sarcomas and p53 Mutations. Mol Med 1998;4:365-72. [DOI: 10.1007/bf03401743] [Cited by in Crossref: 23] [Article Influence: 1.0] [Reference Citation Analysis]
281 Arif E, Vibhuti A, Deepak D, Singh B, Siddiqui MS, Pasha MA. COX2 and p53 risk-alleles coexist in COPD. Clin Chim Acta 2008;397:48-50. [PMID: 18692035 DOI: 10.1016/j.cca.2008.07.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
282 Fracasso PM. Overcoming drug resistance in ovarian carcinoma. Curr Oncol Rep 2001;3:19-26. [DOI: 10.1007/s11912-001-0038-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
283 Backus H, Wouters D, Ferreira C, van Houten V, Brakenhoff R, Pinedo H, Peters G. Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. European Journal of Cancer 2003;39:1310-7. [DOI: 10.1016/s0959-8049(03)00204-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
284 Karpati G, Nalbantoglu J. The principles of molecular therapies for glioblastoma. Int Rev Neurobiol 2003;55:151-63. [PMID: 12968535 DOI: 10.1016/s0074-7742(03)01006-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
285 Roth JA, Grammer SF, Swisher SG, Nemunaitis J, Merritt J, Meyn RE. Gene replacement strategies for treating non-small cell lung cancer. Seminars in Radiation Oncology 2000;10:333-42. [DOI: 10.1053/srao.2000.9127] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
286 Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81-137. [PMID: 10549356 DOI: 10.1016/s0065-230x(08)60785-x] [Cited by in Crossref: 572] [Cited by in F6Publishing: 260] [Article Influence: 24.9] [Reference Citation Analysis]
287 Wu H, Leng RP. UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation. Cell Cycle 2011;10:1912-5. [PMID: 21558803 DOI: 10.4161/cc.10.12.15882] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
288 DeLeo AB, Whiteside TL. Development of multi-epitope vaccines targeting wild-type sequence p53 peptides. Expert Rev Vaccines 2008;7:1031-40. [PMID: 18767952 DOI: 10.1586/14760584.7.7.1031] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
289 Franco R, Nicoletti G, Lombardi A, Di Domenico M, Botti G, Zito Marino F, Caraglia M. Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs. Expert Opin Biol Ther 2013;13:51-66. [PMID: 22998482 DOI: 10.1517/14712598.2012.725720] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
290 Norberg T, Klaar S, Lindqvist L, Lindahl T, Ahlgren J, Bergh J. Enzymatic Mutation Detection Method Evaluated for Detection of p53 Mutations in cDNA from Breast Cancers. Clinical Chemistry 2001;47:821-8. [DOI: 10.1093/clinchem/47.5.821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
291 Järvinen TA, Holli K, Kuukasjärvi T, Isola JJ. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998;77:2267-73. [PMID: 9649144 DOI: 10.1038/bjc.1998.377] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 3.8] [Reference Citation Analysis]
292 Shields PG, Harris CC. Cancer Risk and Low-Penetrance Susceptibility Genes in Gene-Environment Interactions. JCO 2000;18:2309-15. [DOI: 10.1200/jco.2000.18.11.2309] [Cited by in Crossref: 195] [Cited by in F6Publishing: 59] [Article Influence: 8.9] [Reference Citation Analysis]
293 Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN, Ronai Z. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 1998;12:2658-63. [PMID: 9732264 DOI: 10.1101/gad.12.17.2658] [Cited by in Crossref: 224] [Cited by in F6Publishing: 222] [Article Influence: 9.3] [Reference Citation Analysis]
294 Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI, Carbone DP. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999;117:244-51. [PMID: 10444254 DOI: 10.1046/j.1365-2249.1999.00913.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 2.2] [Reference Citation Analysis]
295 Lee YL, Chen W, Tsai WK, Lee JC, Chiou HL, Shih CM, Wang YC. Polymorphisms of p53 and p21 genes in chronic obstructive pulmonary disease. J Lab Clin Med. 2006;147:228-233. [PMID: 16697770 DOI: 10.1016/j.lab.2005.12.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
296 Thor AD, Liu S, Moore Ii DH, Shi Q, Edgerton SM. p21WAF1/CIP1 Expression in breast cancers: associations with p53 and outcome. Breast Cancer Res Treat 2000;61:33-43. [DOI: 10.1023/a:1006455526894] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
297 Mahanta S, Pilla S, Paul S. Design of novel Geldanamycin analogue hsp90 alpha-inhibitor in silico for breast cancer therapy. Medical Hypotheses 2013;81:463-9. [DOI: 10.1016/j.mehy.2013.06.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
298 Tammemagi MC, McLaughlin JR, Mullen JB, Bull SB, Johnston MR, Tsao MS, Casson AG. A study of smoking, p53 tumor suppressor gene alterations and non-small cell lung cancer. Ann Epidemiol 2000;10:176-85. [PMID: 10813511 DOI: 10.1016/s1047-2797(99)00048-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
299 Li S, Li B, Wang J, Zhang D, Liu Z, Zhang Z, Zhang W, Wang Y, Bai D, Guan J. Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction. Oncol Res. 2017;25:93-97. [PMID: 28081737 DOI: 10.3727/096504016x14719078133564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
300 Nafie MS, Arafa K, Sedky NK, Alakhdar AA, Arafa RK. Triaryl dicationic DNA minor-groove binders with antioxidant activity display cytotoxicity and induce apoptosis in breast cancer. Chem Biol Interact 2020;324:109087. [PMID: 32294457 DOI: 10.1016/j.cbi.2020.109087] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
301 Nygren P; SBU-group. Swedish Council on Technology Assessment in Health Care. What is cancer chemotherapy? Acta Oncol. 2001;40:166-174. [PMID: 11441929 DOI: 10.1080/02841860151116204] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
302 Lu P, Yu B, Xu J. Cucurbitacin B regulates immature myeloid cell differentiation and enhances antitumor immunity in patients with lung cancer. Cancer Biother Radiopharm 2012;27:495-503. [PMID: 22746287 DOI: 10.1089/cbr.2012.1219] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
303 Ramani RG, Jacob SG. Prediction of P53 mutants (multiple sites) transcriptional activity based on structural (2D&3D) properties. PLoS One 2013;8:e55401. [PMID: 23468845 DOI: 10.1371/journal.pone.0055401] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
304 Matsukura N, Hoshino A, Igarashi T, Hasegawa H, Okino T, Onda M, Iijima O, Akiyama K, Goto T, Takubo K, Suzuki S, Shimada T. In situ gene transfer and suicide gene therapy of gastric cancer induced by N-ethyl-N'-nitro-N-nitrosoguanidine in dogs. Jpn J Cancer Res 1999;90:1039-49. [PMID: 10551335 DOI: 10.1111/j.1349-7006.1999.tb00852.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
305 Ming X, Matter B, Song M, Veliath E, Shanley R, Jones R, Tretyakova N. Mapping structurally defined guanine oxidation products along DNA duplexes: influence of local sequence context and endogenous cytosine methylation. J Am Chem Soc 2014;136:4223-35. [PMID: 24571128 DOI: 10.1021/ja411636j] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
306 Gomez-manzano C, Fueyo J, Kyritsis AP, Steck PA, Levin VA, Alfred Yung WK, Mcdonnell TJ. Characterization of p53 and p21 Functional Interactions in Glioma Cells en Route to Apoptosis. JNCI Journal of the National Cancer Institute 1997;89:1036-44. [DOI: 10.1093/jnci/89.14.1036] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 3.0] [Reference Citation Analysis]
307 Okada T, Iizuka N, Yamada-Okabe H, Mori N, Tamesa T, Takemoto N, Tangoku A, Hamada K, Nakayama H, Miyamoto T. Gene expression profile linked to p53 status in hepatitis C virus-related hepatocellular carcinoma. FEBS Lett. 2003;555:583-590. [PMID: 14675778 DOI: 10.1016/s0014-5793(03)01345-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
308 Oijen MGCT, Tilanus MGJ, Medema RH, Slootweg PJ. Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression. Journal of Oral Pathology & Medicine 1998;27:367-75. [DOI: 10.1111/j.1600-0714.1998.tb01969.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
309 Marcinkute M, Afshinjavid S, Fatokun AA, Javid FA. Fluoxetine selectively induces p53-independent apoptosis in human colorectal cancer cells. European Journal of Pharmacology 2019;857:172441. [DOI: 10.1016/j.ejphar.2019.172441] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
310 Essner R, Kuo CT, Wang H, Wen DR, Turner RR, Nguyen T, Hoon DS. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer 1998;82:309-16. [PMID: 9445187 DOI: 10.1002/(sici)1097-0142(19980115)82:2<317::aid-cncr10>3.0.co;2-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
311 Angeli D, Salvi S, Tedaldi G. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? Int J Mol Sci 2020;21:E1128. [PMID: 32046255 DOI: 10.3390/ijms21031128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
312 Posner MR, Johnston PG, Tishler RB, Andersen J, Fiorentino M, Busse PM, Cavacini LA, Colevas AD, Clark J, Norris CM. The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck. The Oncologist 1998;3:424-31. [DOI: 10.1634/theoncologist.3-6-424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
313 Baas IO, Offerhaus GJ, Hruban RH. Interactions between cytomegalovirus and the p53 tumor suppressor gene in atherosclerotic vascular disease. Clin Microbiol Infect 1997;3:393-4. [PMID: 11864147 DOI: 10.1111/j.1469-0691.1997.tb00273.x] [Reference Citation Analysis]
314 Choi BY, Joo JC, Lee YK, Jang IS, Park SJ, Park YJ. Anti-cancer effect of Scutellaria baicalensis in combination with cisplatin in human ovarian cancer cell. BMC Complement Altern Med 2017;17:277. [PMID: 28545442 DOI: 10.1186/s12906-017-1776-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
315 Ercan C, van Diest PJ, van der Ende B, Hinrichs J, Bult P, Buerger H, van der Wall E, Derksen PW. p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast. Cell Oncol (Dordr) 2012;35:111-8. [PMID: 22354696 DOI: 10.1007/s13402-012-0071-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
316 Wang Y, Lee P, Shih C, Chen H, Lee C, Chang Y, Hsu Y, Liang Y, Wang L, Han W, Wang Y. Damage formation and repair efficiency in the p53 gene of cell lines and blood lymphocytes assayed by multiplex long quantitative polymerase chain reaction. Analytical Biochemistry 2003;319:206-15. [DOI: 10.1016/s0003-2697(03)00330-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
317 Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, Whiteside TL, DeLeo AB. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 2000;165:5938-44. [PMID: 11067956 DOI: 10.4049/jimmunol.165.10.5938] [Cited by in Crossref: 69] [Cited by in F6Publishing: 51] [Article Influence: 3.1] [Reference Citation Analysis]
318 Lindahl T, Engel G, Ahlgren J, Klaar S, Bjöhle J, Lindman H, Andersson J, von Schoultz E, Bergh J. Can Axillary Dissection be Avoided by Improved Molecular Biological Diagnosis? Acta Oncologica 2009;39:319-26. [DOI: 10.1080/028418600750013087] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
319 Mazur SJ, Sakaguchi K, Appella E, Wang XW, Harris CC, Bohr VA. Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA involves the C-terminal domain. J Mol Biol 1999;292:241-9. [PMID: 10493872 DOI: 10.1006/jmbi.1999.3064] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis]
320 Clayman GL, Dreiling L. Local delivery for gene therapy. Curr Oncol Rep 1999;1:138-43. [DOI: 10.1007/s11912-999-0024-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
321 Zheng A, Castren K, Säily M, Savolainen ER, Koistinen P, Vähäkangas K. p53 status of newly established acute myeloid leukaemia cell lines. Br J Cancer 1999;79:407-15. [PMID: 10027306 DOI: 10.1038/sj.bjc.6690064] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
322 Pandit S, Wasekar N, Badarkhe G, Yasam VR, Nagarkar R. Acute lymphoblastic leukemia to acute myeloid leukemia: an unusual case report of lineage switching. Hematol Transfus Cell Ther 2020:S2531-1379(20)30099-7. [PMID: 32737020 DOI: 10.1016/j.htct.2020.06.007] [Reference Citation Analysis]
323 Saini KS, Walker NI. Biochemical and molecular mechanisms regulating apoptosis. Mol Cell Biochem. 1998;178:9-25. [PMID: 9546577 DOI: 10.1023/a:1006891430596] [Cited by in Crossref: 38] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
324 Yoo GH, Piechocki MP, Oliver J, Lonardo F, Zumstein L, Lin H, Kim H, Shibuya TY, Shehadeh N, Ensley JF. Enhancement of Ad-p53 Therapy with Docetaxel in Head and Neck Cancer: . The Laryngoscope 2004;114:1871-9. [DOI: 10.1097/01.mlg.0000147914.51239.ed] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
325 Whisler LC, Wood NB, Caldarelli DD, Hutchinson JC, Panje WR, Friedman M, Preisler HD, Leurgans S, Nowak J, Coon JS. Regulators of Proliferation and Apoptosis in Carcinoma of the Larynx. Laryngoscope 1998;108:630-8. [DOI: 10.1097/00005537-199805000-00002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
326 Shah H, Rawal Mahajan S. Photoaging: New insights into its stimulators, complications, biochemical changes and therapeutic interventions. Biomedicine & Aging Pathology 2013;3:161-9. [DOI: 10.1016/j.biomag.2013.05.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
327 Casson AG, Evans SC, Gillis A, Porter GA, Veugelers P, Darnton SJ, Guernsey DL, Hainaut P. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg. 2003;125:1121-1131. [PMID: 12771886 DOI: 10.1067/mtc.2003.176] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
328 Sansom OJ, Clarke AR. P53 null mice: damaging the hypothesis? Mutat Res 2000;452:149-62. [PMID: 11024475 DOI: 10.1016/s0027-5107(00)00089-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
329 Kankaya D, Kiremitci S, Tulunay O, Baltaci S. Gelsolin, NF-κB, and p53 expression in clear cell renal cell carcinoma: Impact on outcome. Pathol Res Pract 2015;211:505-12. [PMID: 25908108 DOI: 10.1016/j.prp.2015.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
330 Ghosh R, Bhowmik S, Bagchi A, Das D, Ghosh S. Chemotherapeutic potential of 9-phenyl acridine: biophysical studies on its binding to DNA. Eur Biophys J 2010;39:1243-9. [DOI: 10.1007/s00249-010-0577-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
331 Ikeda K, Sakai K, Yamamoto R, Hareyama H, Tsumura N, Watari H, Shimizu M, Minakami H, Sakuragi N. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer 2003;13:776-84. [PMID: 14675314 DOI: 10.1111/j.1525-1438.2003.13381.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
332 Li P, Bui T, Gray D, Klamut HJ. Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53. Breast Cancer Res Treat 1998;48:273-86. [DOI: 10.1023/a:1005961705860] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
333 Bates S, Hickman ES, Vousden KH. Reversal of p53-induced cell-cycle arrest. Mol Carcinog 1999;24:7-14. [PMID: 10029405 DOI: 10.1002/(sici)1098-2744(199901)24:1<7::aid-mc2>3.0.co;2-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
334 Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 2007;96:639-45. [PMID: 17285125 DOI: 10.1038/sj.bjc.6603616] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
335 Chen S, Chen J, Xi W, Xu W, Yin G. Clinical Therapeutic Effect and Biological Monitoring of p53 Gene in Advanced Hepatocellular Carcinoma. American Journal of Clinical Oncology 2014;37:24-9. [DOI: 10.1097/coc.0b013e3181fe4688] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
336 Scholl FA, McLoughlin P, Ehler E, de Giovanni C, Schäfer BW. DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J Cell Biol 2000;151:495-506. [PMID: 11062252 DOI: 10.1083/jcb.151.3.495] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 3.4] [Reference Citation Analysis]
337 Musumarra G, Condorelli DF, Costa AS, Fichera M. A multivariate insight into the in vitro antitumour screen database of the National Cancer Institute: classification of compounds, similarities among cell lines and the influence of molecular targets. J Comput Aided Mol Des 2001;15:219-34. [PMID: 11289076 DOI: 10.1023/a:1008171426412] [Cited by in Crossref: 17] [Article Influence: 0.8] [Reference Citation Analysis]
338 Vinyals A, Peinado MA, Gonzalez-Garrigues M, Monzó M, Bonfil RD, Fabra A. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein. Gene Ther. 1999;6:22-33. [PMID: 10341872 DOI: 10.1038/sj.gt.3300786] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
339 Malkin D. The role of p53 in human cancer. J Neurooncol 2001;51:231-43. [PMID: 11407595 DOI: 10.1023/a:1010636426860] [Cited by in Crossref: 35] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
340 Ishii HH, Gobé GC, Pan W, Yoneyama J, Ebihara Y. Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and p53 protein expression. J Gastroenterol Hepatol. 2002;17:966-972. [PMID: 12167117 DOI: 10.1046/j.1440-1746.2002.02805.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
341 Lukas J, Niu N, Press MF. p53 mutations and expression in breast carcinoma in situ. Am J Pathol 2000;156:183-91. [PMID: 10623666 DOI: 10.1016/S0002-9440(10)64718-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
342 Kozlenko M, Vol A, Zusman I. Stability–variability conflict as a reason for cancer: physical and social aspects. Medical Hypotheses 2001;57:648-54. [DOI: 10.1054/mehy.2001.1434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
343 Huang C, Yokomise H, Miyatake A. Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers. Future Oncology 2007;3:83-93. [DOI: 10.2217/14796694.3.1.83] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
344 Kalra N, Roy P, Prasad S, Shukla Y. RETRACTED: Resveratrol induces apoptosis involving mitochondrial pathways in mouse skin tumorigenesis. Life Sci 2008;82:348-58. [PMID: 18201729 DOI: 10.1016/j.lfs.2007.11.006] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 5.0] [Reference Citation Analysis]
345 Suzuki S, Uozumi K, Hanada S, Lin XY, Ohno N, Takatsuka Y, Takeuchi S, Owatari S, Takeshita T, Arima T. A novel c-kit positive biphenotypic acute leukemia cell line, TMBL-1, carrying a p53 point mutation. Leuk Lymphoma 2003;44:849-57. [PMID: 12802925 DOI: 10.1080/1042819031000068061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
346 Hall SJ, Chen SH, Woo SL. The promise and reality of cancer gene therapy. Am J Hum Genet 1997;61:785-9. [PMID: 9382085 DOI: 10.1086/514898] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
347 Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther. 2000;11:1397-1406. [PMID: 10910137 DOI: 10.1089/10430340050057477] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 3.6] [Reference Citation Analysis]
348 Hatano K, Kumar B, Zhang Y, Coulter JB, Hedayati M, Mears B, Ni X, Kudrolli TA, Chowdhury WH, Rodriguez R, DeWeese TL, Lupold SE. A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation. Nucleic Acids Res 2015;43:4075-86. [PMID: 25845598 DOI: 10.1093/nar/gkv273] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
349 Heo HY, Chung S, Kim YT, Kim DH, Seo TS. A valveless rotary microfluidic device for multiplex point mutation identification based on ligation-rolling circle amplification. Biosensors and Bioelectronics 2016;78:140-6. [DOI: 10.1016/j.bios.2015.11.039] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
350 Kawai T, Hiroi S, Nakanishi K, Sakurai Y, Torikata C. Abnormalities in chromosome 17 and p53 in lung carcinoma cells detected by fluorescence in situ hybridization. Pathol Int 2004;54:413-9. [PMID: 15144400 DOI: 10.1111/j.1440-1827.2004.01635.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
351 Mizumoto K, Sato N, Kusumoto M, Niiyama H, Maehara N, Nishio S, Li Z, Ogawa T, Tanaka M. Diverse effects of 9-hydroxyellipticine on the chemosensitivity of human pancreatic cancer cells harboring p53 mutations. Cancer Letters 2000;149:85-94. [DOI: 10.1016/s0304-3835(99)00345-6] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
352 Dash S, Chava S, Aydin Y, Chandra PK, Ferraris P, Chen W, Balart LA, Wu T, Garry RF. Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response. Viruses 2016;8:E150. [PMID: 27223299 DOI: 10.3390/v8050150] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 7.7] [Reference Citation Analysis]
353 Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem. 2005;280:39373-39379. [PMID: 16176931 DOI: 10.1074/jbc.M500022200] [Cited by in Crossref: 89] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
354 Yokoyama Y, Takahashi Y, Morishita S, Hashimoto M, Tamaya T. Introduction of p21(Waf1/Cip1) gene into a carcinoma cell line of the uterine cervix with inactivated p53. Cancer Lett 1997;116:233-9. [PMID: 9215868 DOI: 10.1016/s0304-3835(97)00193-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
355 Swisher SG, Roth JA, Carbone DP. Genetic and immunologic therapies for lung cancer. Seminars in Oncology 2002;29:95-101. [DOI: 10.1053/sonc.2002.31530] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
356 Shackelford RE, Kaufmann WK, Paules RS. Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ Health Perspect 1999;107 Suppl 1:5-24. [PMID: 10229703 DOI: 10.1289/ehp.99107s15] [Cited by in Crossref: 114] [Cited by in F6Publishing: 120] [Article Influence: 5.2] [Reference Citation Analysis]
357 DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A 1997;94:4000-4. [PMID: 9108094 DOI: 10.1073/pnas.94.8.4000] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 3.0] [Reference Citation Analysis]
358 Denardo SJ, Kroger LA, Lamborn KR, Miers LA, O'donnell RT, Kukis DL, Richman CM, Denardo GL. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer 1997;80:2583-90. [DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2583::aid-cncr34>3.0.co;2-6] [Cited by in Crossref: 20] [Article Influence: 0.8] [Reference Citation Analysis]
359 Lumachi F, Basso S. Apoptosis: life through planned cellular death regulating mechanisms, control systems, and relations with thyroid diseases. Thyroid 2002;12:27-34. [PMID: 11838727 DOI: 10.1089/105072502753451931] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
360 Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002;9:553-66. [DOI: 10.1038/sj.cgt.7700472] [Cited by in Crossref: 125] [Cited by in F6Publishing: 112] [Article Influence: 6.3] [Reference Citation Analysis]
361 Wu Q, Wang H, Liu L, Zhu K, Yu W, Guo J. Hsa_circ_0001546 acts as a miRNA-421 sponge to inhibit the chemoresistance of gastric cancer cells via ATM/Chk2/p53-dependent pathway. Biochem Biophys Res Commun 2020;521:303-9. [PMID: 31668372 DOI: 10.1016/j.bbrc.2019.10.117] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
362 Jung CK, Jung JH, Park GS, Lee A, Kang CS, Lee KY. Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer. Pathol Int 2006;56:503-9. [PMID: 16930330 DOI: 10.1111/j.1440-1827.2006.01998.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
363 Blumenthal RD, Leone E, Goldenberg DM, Rodriguez M, Modrak D. Anin vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression. Int J Cancer 2004;108:293-300. [DOI: 10.1002/ijc.11534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
364 Tue NT, Yoshioka Y, Yamaguchi M. NF-Y transcriptionally regulates the Drosophila p53 gene. Gene 2011;473:1-7. [PMID: 21044877 DOI: 10.1016/j.gene.2010.10.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
365 Ueda J, Yoshida H, Mamada Y, Taniai N, Yoshioka M, Hirakata A, Kawano Y, Mizuguchi Y, Shimizu T, Kanda T, Takata H, Kondo R, Uchida E. Evaluation of positive ductal margins of biliary tract cancer in intraoperative histological examination. Oncol Lett 2018;16:6677-84. [PMID: 30405808 DOI: 10.3892/ol.2018.9479] [Reference Citation Analysis]
366 Yamasaki M, Miyata H, Fujiwara Y, Takiguchi S, Nakajima K, Nishida T, Yasuda T, Matsuyama J, Mori M, Doki Y. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2010;17:634-642. [PMID: 19941080 DOI: 10.1245/s10434-009-0851-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
367 Ananthaswamy HN, Ouhtit A, Evans RL, Gorny A, Khaskina P, Sands AT, Conti CJ. Persistence of p53 mutations and resistance of keratinocytes to apoptosis are associated with the increased susceptibility of mice lacking the XPC gene to UV carcinogenesis. Oncogene 1999;18:7395-8. [PMID: 10602497 DOI: 10.1038/sj.onc.1203147] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
368 Klinge U, Rosch R, Junge K, Krones CJ, Stumpf M, Lynen-Jansen P, Mertens PR, Schumpelick V. Different matrix micro-environments in colon cancer and diverticular disease. Int J Colorectal Dis. 2007;22:515-520. [PMID: 17021746 DOI: 10.1007/s00384-006-0199-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
369 Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma: p53 Alterations and Ovarian Carcinoma Prognosis. Cancer 2000;89:2006-17. [DOI: 10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.0.co;2-7] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
370 Coursen JD, Bennett WP, Khan MA, Forrester K, Pietenpol JA, Harris CC. Differential effects ofp53 mutants on the growth of human bronchial epithelial cells. Mol Carcinog 1997;19:191-203. [DOI: 10.1002/(sici)1098-2744(199707)19:3<191::aid-mc7>3.0.co;2-h] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
371 Olumi AF. A critical analysis of the use of p53 as a marker for management of bladder cancer. Urol Clin North Am 2000;27:75-82, ix. [PMID: 10696247 DOI: 10.1016/s0094-0143(05)70236-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
372 Li YF, Zhang HT, Xin L. Hyaluronic acid-modified polyamidoamine dendrimer G5-entrapped gold nanoparticles delivering METase gene inhibits gastric tumor growth via targeting CD44+ gastric cancer cells. J Cancer Res Clin Oncol 2018;144:1463-73. [PMID: 29858680 DOI: 10.1007/s00432-018-2678-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]